[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 908
1. Maheshwari V, Sharma R, Mehdi G, Prasad S, Hakim S: Clear cell adenocarcinoma cervix: a diagnostic dilemma. Indian J Pathol Microbiol; 2009 Apr-Jun;52(2):282-3
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma cervix: a diagnostic dilemma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Adenocarcinoma, Clear Cell / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


2. Li F, Awale S, Tezuka Y, Kadota S: Cytotoxic constituents of propolis from Myanmar and their structure-activity relationship. Biol Pharm Bull; 2009 Dec;32(12):2075-8
National BioResource Project. culture/stock collections - NBRP resources .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirteen cycloartane-type tritepenes (1-13) and four prenylated flavanones (14-17) isolated from propolis collected in Myanmar, were evaluated for their cytotoxic activity against a panel of six different cancer cell lines; three murine cancer cell lines (colon 26-L5 carcinoma, B16-BL6 melanoma, and Lewis lung carcinoma) and three human cancer cell lines (lung A549 adenocarcinoma, cervix HeLa adenocarcinoma and HT-1080 fibrosarcoma).
  • In addition, (2S)-5,7-dihydroxy-4'-methoxy-8,3'-diprenylflavanone (14) exhibited strong cytotoxicity against all the tested cancer cell lines with the IC(50) values ranging from 14.0 to 26.4 microM.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952433.001).
  • [ISSN] 1347-5215
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavanones; 0 / Triterpenes; 511-64-8 / cycloartane; 9009-62-5 / Propolis
  •  go-up   go-down


3. Takai N, Hayashita C, Nakamura S, Narahara H, Matsumoto H: A Case of Villoglandular Papillary Adenocarcinoma of the Uterine Cervix Diagnosed during Early Pregnancy Followed by Successful Term Delivery. Case Rep Med; 2010;2010:314547

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Case of Villoglandular Papillary Adenocarcinoma of the Uterine Cervix Diagnosed during Early Pregnancy Followed by Successful Term Delivery.
  • Villoglandular papillary adenocarcinoma (VPA) is a very rare subtype of adenocarcinoma of the uterine cervix, but a well-recognized variant of cervical adenocarcinoma with a favorable prognosis and generally occurring in women of child-bearing age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1989 May 1;63(9):1773-9 [2702584.001]
  • [Cites] Obstet Gynecol. 1995 May;85(5 Pt 2):906-8 [7724158.001]
  • [Cites] Int J Gynecol Pathol. 1993 Jan;12(1):1-7 [8418074.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):147-52 [8995564.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):310-3 [11330967.001]
  • [Cites] J Med Assoc Thai. 2001 Jun;84(6):882-8 [11556470.001]
  • [Cites] Eur J Surg Oncol. 2008 May;34(5):606-8 [17643913.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):64-70 [14751140.001]
  • [Cites] Tohoku J Exp Med. 2004 Apr;202(4):305-10 [15109129.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):883-7 [16088403.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):192-4 [16266744.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):168-71 [16325894.001]
  • [Cites] BJOG. 2003 Jun;110(6):627-9 [12798484.001]
  • (PMID = 20589215.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2892664
  •  go-up   go-down


Advertisement
4. Baalbergen A, Ewing-Graham PC, Eijkemans MJ, Helmerhorst TJ: Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality. Int J Cancer; 2007 Jul 1;121(1):106-10
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of adenocarcinoma of the uterine cervix: p53 expression correlates with higher incidence of mortality.
  • We investigated the significance of prognostic markers-estrogen receptor, progesterone receptor, p53, MIB-1 and bcl-2 - in adenocarcinoma of the uterine cervix.
  • In 101 patients with primary cervical adenocarcinoma, treated from 1989 to 2000, we evaluated clinical parameters in relation to these prognostic markers.
  • In conclusion, it does not seems useful to determine estrogen receptor, progesterone receptor, MIB-1 or bcl-2 in cervical adenocarcinomas as an indication of prognosis: survival is not influenced by presence or absence.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / mortality. Tumor Suppressor Protein p53 / metabolism. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17354237.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


5. Luciani S, Bertoletti L, Vergnon JM: [Endoscopic treatment of endobronchial metastases from adenocarcinoma of the uterine cervix]. Rev Mal Respir; 2010 Sep;27(7):759-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic treatment of endobronchial metastases from adenocarcinoma of the uterine cervix].
  • [Transliterated title] Traitement endoscopique de métastases endobronchiques d'un adénocarcinome du col utérin.
  • They are very rarely due to uterine cervical cancer.
  • CASE REPORT: We present the extraordinary case of a woman with endobronchial metastases from an adenocarcinoma of the uterine cervix.
  • Pathological analysis of this tumour confirmed the diagnosis and found papilloma virus infection.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Bronchial Neoplasms / secondary. Bronchial Neoplasms / surgery. Bronchoscopy. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 SPLF. Published by Elsevier Masson SAS. All rights reserved.
  • (PMID = 20863978.001).
  • [ISSN] 1776-2588
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Papastefanou I, Panagopoulos P, Samolis S, Karadaglis S, Katsoulis M: Minimal deviation adenocarcinoma of the cervix in a patient with a high-grade cervical squamous intraepithelial lesion: case report and review of the literature. Eur J Gynaecol Oncol; 2010;31(2):227-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal deviation adenocarcinoma of the cervix in a patient with a high-grade cervical squamous intraepithelial lesion: case report and review of the literature.
  • Minimal deviation cervical adenocarcinoma, otherwise known as adenoma malignum, is a rare and particularly well differentiated type of cervical adenocarcinoma, and is often misdiagnosed because of its benign-looking histological features.
  • Adenoma malignum represents only 1-3% of all cervical adenocarcinomas.
  • We present the case of a 55-year-old woman diagnosed as having microinvasive minimal deviation of the adenocarcinoma cervix, after conisation for a high-grade cervical squamous intraepithelial lesion.
  • The consequent cone biopsy because of CIN3, provided us with a definite diagnosis of adenoma malignum.
  • [MeSH-major] Adenocarcinoma / pathology. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20527250.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Bodner K, Laubichler P, Kimberger O, Czerwenka K, Zeillinger R, Bodner-Adler B: Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters. Anticancer Res; 2010 Apr;30(4):1341-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters.
  • OBJECTIVE: The expression of oestrogen and progesterone receptors in patients with adenocarcinoma of the uterine cervix was examined in order to determine their influence on prognosis and to evaluate the association between the steroid receptor expression and various clinicopathologic parameters.
  • PATIENTS AND METHODS: Oestrogen and progesterone receptor expression was investigated by immunohistochemistry from paraffin-embedded tissue in 39 patients with adenocarcinoma of the uterine cervix.
  • CONCLUSION: Oestrogen and progesterone receptors were frequently expressed in adenocarcinoma of the uterine cervix.
  • Thus, the investigation of steroid receptors adds little additional information to the clinical management and fails to play a prognostic role in cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Biomarkers, Tumor / biosynthesis. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530450.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


8. Epstein E, Di Legge A, Måsbäck A, Lindqvist PG, Kannisto P, Testa AC: Sonographic characteristics of squamous cell cancer and adenocarcinoma of the uterine cervix. Ultrasound Obstet Gynecol; 2010 Oct;36(4):512-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic characteristics of squamous cell cancer and adenocarcinoma of the uterine cervix.
  • OBJECTIVE: The objective of this study was to describe the sonographic characteristics of squamous cell cancer (SCC) and adenocarcinoma (AC) of the cervix using transvaginal ultrasound.
  • METHODS: Women with early stage cervical cancer undergoing transvaginal ultrasound examination before surgery were prospectively included.
  • At pathological examination, 34 women had tumors confined to the cervix, three had parametrial invasion and three had vaginal invasion.
  • Color Doppler signals were found in all cases of AC and in 90% (18/20) of cases of SCC, compared with most normal cervical tissue in which virtually no detectable vascularization was found.
  • This knowledge should be useful in the clinical evaluation of cervical tumors.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Carcinoma, Squamous Cell / ultrasonography. Cervix Uteri / ultrasonography. Uterine Cervical Neoplasms / ultrasonography


9. de Carvalho CR, da Silva ID, Pereira JS, de Souza NC, Focchi GR, Ribalta JC: Polymorphisms of p53, GSTM1 and GSTT1, and HPV in uterine cervix adenocarcinoma. Eur J Gynaecol Oncol; 2008;29(6):590-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of p53, GSTM1 and GSTT1, and HPV in uterine cervix adenocarcinoma.
  • OBJECTIVE: To analyze the participation of glutathione-S-transferase (GST) M1 and T1 polymorphisms associated or not with protein p53 polymorphism at codon 72 and in the presence of HPV in the carcinogenesis of uterine cervix adenocarcinoma.
  • METHODS: Forty-three samples of uterine cervix adenocarcinoma were studied and 86 samples of endocervical cells of women without tumors formed the control group.
  • RESULTS: HPV was present in 97.67% of the adenocarcinoma cases and in 31.40% of the control group.
  • CONCLUSION: The presence of GSTT1*0 increased the risk for uterine cervix adenocarcinoma development while the allele GSTT1 had a protective action.
  • The other isoforms did not appear to participate in the carcinogenesis of uterine cervix adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Alphapapillomavirus / isolation & purification. Glutathione Transferase / genetics. Polymorphism, Single Nucleotide / genetics. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115684.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


10. Yahata T, Nishino K, Kashima K, Sekine M, Fujita K, Sasagawa M, Honma S, Kodama S, Tanaka K: Conservative treatment of stage IA1 adenocarcinoma of the uterine cervix with a long-term follow-up. Int J Gynecol Cancer; 2010 Aug;20(6):1063-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative treatment of stage IA1 adenocarcinoma of the uterine cervix with a long-term follow-up.
  • OBJECTIVES: The adenocarcinoma of the uterine cervix tends to arise in women of childbearing age.
  • Conservative treatment by conization is an alternative to a hysterectomy that allows future pregnancy; however, much less is known about the management of adenocarcinoma because of its rarity and relatively short time frame of follow-up.
  • METHODS: All patients diagnosed to have FIGO (International Federation of Gynecology and Obstetrics) stage IA1 cervical adenocarcinoma between 1990 and 2004 with more than 5 years' follow-up at 2 institutions were reviewed.
  • All tumors were endocervical-type adenocarcinoma, and all tumors were grade 1.
  • CONCLUSIONS: Although further studies on the management of microinvasive cervical adenocarcinoma are desirable, conization seems to be acceptable treatment modality for patients with stage IA1 cervical adenocarcinoma who desire to preserve their fertility.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Conization / methods. Neoplasm Recurrence, Local / pathology. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20683418.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Pavelka JC, Bryant DA, Vaccarello L: Adenocarcinoma of the uterine cervix with choriocarcinomatous metastasis. Gynecol Oncol; 2006 May;101(2):346-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the uterine cervix with choriocarcinomatous metastasis.
  • CASE: A 55 year old woman was diagnosed with adenocarcinoma of the cervix, and incompletely treated with only external beam radiation.
  • CONCLUSION: Choriocarcinomatous dedifferentiation of cervical adenocarcinoma is extremely rare, with only one other case reported in the literature.
  • [MeSH-major] Adenocarcinoma / pathology. Choriocarcinoma / secondary. Uterine Cervical Neoplasms / pathology. Uterine Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430947.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Takai N, Hayashita C, Nakamura S, Narahara H, Matsumoto H: Villoglandular papillary adenocarcinoma of the uterine cervix diagnosed during pregnancy. Eur J Gynaecol Oncol; 2010;31(5):573-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix diagnosed during pregnancy.
  • Villoglandular papillary adenocarcinoma (VPA) is a very rare subtype of adenocarcinoma of the uterine cervix but a well recognized variant of cervical adenocarcinoma with a favorable prognosis generally occurring in women of child-bearing age.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / pathology. Pregnancy Complications, Neoplastic / diagnosis. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


13. Schmidt D, Horn LC, Kommoss F: [Histopathology of squamous cell carcinoma and adenocarcinoma of the uterine cervix]. Pathologe; 2005 Jul;26(4):255-61
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Histopathology of squamous cell carcinoma and adenocarcinoma of the uterine cervix].
  • [Transliterated title] Histopathologie des Plattenepithelkarzinoms und des Adenokarzinoms der Cervix uteri.
  • The introduction of a screening programme for carcinoma of the cervix uteri has lead to a reduction in the number of invasive carcinomas and to a relative increase in the frequency of preinvasive cervical lesions.
  • The most frequent type of invasive cancer of the cervix is squamous cell carcinoma.
  • Adenocarcinomas are much more infrequent.
  • Among the various forms of adenocarcinoma, the mucinous subtype is the most frequent, either as endocervical or interstinal subtype.
  • Great concern in daily diagnosis causes the adenoma malignum (minimal deviation adenocarcinoma), since this type of adenocarcinoma demonstrates only minor cytological atypia and greatly resembles the different types of endocervical glandular hyperplasia.A report on a cervical carcinoma should always include the typing and grading of the tumor.
  • Immunohistochemical stains are often useful to distinguish the various types of primary cervical cancer and to distinguish these from metastatic lesions.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):327-46 [12352182.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12):1540-5 [11717545.001]
  • [Cites] Int J Gynecol Pathol. 2002 Apr;21(2):125-33 [11917221.001]
  • [Cites] Gynecol Oncol. 1999 Dec;75(3):345-8 [10600287.001]
  • [Cites] J Epidemiol Biostat. 2001;6(1):7-43 [11385777.001]
  • [Cites] Histopathology. 2002 Sep;41(3):185-207 [12207781.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1996 Feb;64(2):201-5 [8820003.001]
  • [Cites] Am J Surg Pathol. 1985 Dec;9(12):883-9 [3934992.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1158-71 [7573674.001]
  • [Cites] Int J Gynecol Pathol. 1993 Jul;12(3):264-9 [7688354.001]
  • [Cites] Int J Epidemiol. 1988 Sep;17(3):501-8 [3209326.001]
  • [Cites] Zentralbl Gynakol. 2001 May;123(5):255-65 [11449618.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Dec;87(2):183-9 [10597972.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):915-21 [9255254.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2471-83 [11745305.001]
  • (PMID = 15915328.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Shimada M, Kigawa J, Nishimura R, Hiura M, Hatae M, Takehara K, Sato A, Kurachi H, Mizunuma H, Sugiyama T: Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy after radical surgery: SGSG/TGCU Intergroup Surveillance. J Clin Oncol; 2009 May 20;27(15_suppl):5585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy after radical surgery: SGSG/TGCU Intergroup Surveillance.
  • : 5585 Background: We conducted the present surveillance to clarify the significance of adjuvant radiotherapy and the cause of poor outcome of adenocarcinoma (AC).
  • METHODS: A total of 825 patients with FIGO stage Ib-IIb cervical cancer, who underwent type III radical hysterectomy in 10 institutes of SGSG/ TGCU Intergroup between April 1997 and March 2003, were enrolled in this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962392.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Monk B, Mas L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts NW, Pandite LN: A randomized phase II study: Pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC). J Clin Oncol; 2009 May 20;27(15_suppl):5520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II study: Pazopanib (P) versus lapatinib (L) versus combination of pazopanib/lapatinib (L+P) in advanced and recurrent cervical cancer (CC).
  • METHODS: Patients (pts) with measurable stage IVB, persistent or recurrent squamous or adenocarcinoma of the cervix not amenable to curative therapy; 0-1 prior regimens in the metastatic setting; ECOG PS 0-1; were randomized 1:1:1 to each of 3 treatment groups; not prescreened for EGFR or HER2 status.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962484.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tsubamoto H, Wada R, Kanazawa R, Komori S, Maeda H, Hirota S, Adachi S: Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16518

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant transarterial chemoembolization (TACE) using cisplatin with the combination of dose-dense intravenous administration of paclitaxel for the locally advanced cervical adenocarcinoma.
  • : e16518 Background: Adenocarcinoma (including adenosquamous carcinoma) of the uterine cervix has a tendency to early lymph node metastasis and is resistant to radiation therapy, thus results in poor prognosis compared with squamous cell carcinoma.
  • Neoadjuvant chemotherapy (NAC) followed by radical hysterectomy (RH) for bulky cervical adenocarcinoma seems to be an alternative therapy to primary radiation.
  • Eligible criteria were as follows: Histologically diagnosed cervical adeno or adenosquamous carcinoma with FIGO stage IB2-IVA, Age < or equal to 75, PS 0-2, given informed consent.
  • The NAC regimen consisted of paclitaxel (60mg/m2, iv, D1, D8, D15) and cisplatin (70 mg/m2, trans-uterine arterial infusion followed by embolization using the gelform, D2) repeated every 3 weeks for 2-3 cycles, followed by RH.
  • CONCLUSIONS: TACE with cisplatin and dose dense paclitaxel in the neoadjuvant setting is feasible and effective for cervical adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Zereu M, Zettler CG, Cambruzzi E, Zelmanowicz A: Herpes simplex virus type 2 and Chlamydia trachomatis in adenocarcinoma of the uterine cervix. Gynecol Oncol; 2007 Apr;105(1):172-5
MedlinePlus Health Information. consumer health - Genital Herpes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Herpes simplex virus type 2 and Chlamydia trachomatis in adenocarcinoma of the uterine cervix.
  • INTRODUCTION: Adenocarcinoma of the uterine cervix (AC) occurs in 15-20% of primary cervical neoplasias.
  • CONCLUSIONS: In our series HSV-2 DNA and CT DNA were not found to be integrated to the genome of adenocarcinoma of the uterine cervix and do not seem to be a co-factor for HPV on the etiology of this histologic subtype.
  • [MeSH-major] Adenocarcinoma / epidemiology. Chlamydia Infections / epidemiology. Chlamydia trachomatis / isolation & purification. Herpes Genitalis / epidemiology. Herpesvirus 2, Human / isolation & purification. Uterine Cervical Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Chlamydia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Chlamydia Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17188342.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Viral
  •  go-up   go-down


18. Reynolds EA, Tierney K, Keeney GL, Felix JC, Weaver AL, Roman LD, Cliby WA: Analysis of outcomes of microinvasive adenocarcinoma of the uterine cervix by treatment type. Obstet Gynecol; 2010 Nov;116(5):1150-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of outcomes of microinvasive adenocarcinoma of the uterine cervix by treatment type.
  • OBJECTIVE: To estimate the risk of metastatic disease in microinvasive adenocarcinoma of the cervix in a large cohort.
  • One patient with stage IA1 cancer had micrometastasis to a pelvic lymph node.
  • CONCLUSION: The management of microinvasive adenocarcinoma remains controversial, and radical therapy is applied more frequently to microinvasive adenocarcinoma than microinvasive squamous cell carcinoma of the cervix.
  • Our data suggest that microinvasive adenocarcinoma is amenable to treatment with nonradical surgery.
  • [MeSH-major] Adenocarcinoma / surgery. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20966701.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  •  go-up   go-down


19. Rittiluechai K, Buranawit K, Tanapat Y: The treatment outcome of adenocarcinoma of uterine cervix at Phramongkutklao Hospital. J Med Assoc Thai; 2010 Nov;93 Suppl 6:S13-21
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The treatment outcome of adenocarcinoma of uterine cervix at Phramongkutklao Hospital.
  • OBJECTIVE: To determine the survival rate of patients with adenocarcinoma of the cervix after completing treatment at Phramongkutklao Hospital.
  • MATERIAL AND METHOD: Retrospective review of medical records of 229 patients with adenocarcinoma of the cervix who had completed treatment at Phramongkutklao Hospital between October 1991 to September 2006.
  • RESULTS: Overall 2, 5 and 10-year survival for patients with adenocarcinoma of the cervix was 78.9%, 70.1% and 67.0%, respectively.
  • Five-year survival of patients with locally advanced adenocarcinoma of the cervix treated with concurrent chemoradiation was comparable to that of patients treated with radiation alone (64.0 vs. 62.4%).
  • CONCLUSION: Survival of patients with adenocarcinoma of the cervix shows a direct correlation with stage.
  • Adjuvant hysterectomy after radiation in adenocarcinoma of the cervix stage IIB and IIIB did not improve long-term survival.
  • [MeSH-major] Adenocarcinoma / therapy. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21280512.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


20. Fadare O, Zheng W: Well-differentiated papillary villoglandular adenocarcinoma of the uterine cervix with a focal high-grade component: is there a need for reassessment? Virchows Arch; 2005 Nov;447(5):883-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated papillary villoglandular adenocarcinoma of the uterine cervix with a focal high-grade component: is there a need for reassessment?
  • Well-differentiated villoglandular adenocarcinoma of the uterine cervix is characterized by an exophytic growth pattern with variably sized papillae that are lined by stratified columnar cells with no more than moderate cytologic atypia.
  • The case described herein is an otherwise prototypical well-differentiated villoglandular adenocarcinoma but which was associated with a 4.9-mm focus of poorly differentiated carcinoma at its invasive edge.
  • Our case suggests that well-differentiated villoglandular adenocarcinoma is not a diagnosis that should be unequivocally rendered on a small biopsy since other components may be present and the patients may be undertreated.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Chorionic Villi / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1992 Jul;5(4):426-31 [1495949.001]
  • [Cites] Tohoku J Exp Med. 2004 Apr;202(4):305-10 [15109129.001]
  • [Cites] Gynecol Oncol. 1997 Jan;64(1):147-52 [8995564.001]
  • [Cites] Histopathology. 2002 Sep;41(3):185-207 [12207781.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Sep;86(1):101-3 [10471150.001]
  • [Cites] J Med Assoc Thai. 2001 Jun;84(6):882-8 [11556470.001]
  • [Cites] Int J Gynecol Pathol. 1993 Jan;12(1):1-7 [8418074.001]
  • [Cites] BJOG. 2003 Jun;110(6):627-9 [12798484.001]
  • [Cites] Cancer. 1989 May 1;63(9):1773-9 [2702584.001]
  • [Cites] Mod Pathol. 2005 Apr;18(4):528-34 [15502807.001]
  • [Cites] Gynecol Oncol. 1990 Nov;39(2):221-4 [2227600.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Dec;87(2):183-9 [10597972.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):64-70 [14751140.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1258-64 [15693030.001]
  • [Cites] Gynecol Oncol. 1997 Aug;66(2):327-30 [9264585.001]
  • (PMID = 16088403.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Rubesa-Mihaljević R, Vrdoljak-Mozetic D, Ostojić DV, Stemberger-Papić S, Sindik N, Krasević M: Villoglandular papillary adenocarcinoma of the uterine cervix with aggressive clinical course--a case report. Coll Antropol; 2010 Mar;34(1):291-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix with aggressive clinical course--a case report.
  • Villoglandular papillary adenocarcinoma (VGA) of cervix is an uncommon but well recognized histologic subtype of cervical adenocarcinoma which usually affects young women.
  • We present a case of a 22-year-old woman admitted at our Department for glandular abnormality on cervical smear and episodes of vaginal discharge.
  • In the Pap smear, the cytological features were suspicious but not diagnostic of adenocarcinoma, therefore reported as atypical glandular cells (AGC).
  • Cervical smears examination would be helpful for an early diagnosis of VGA, however the cytologic recognition is often difficult.
  • Further investigation of the pathogenesis, diagnosis and therapy of the tumor is needed.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Severity of Illness Index. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437645.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


22. Tsai CC, Liu YS, Huang EY, Huang SC, Chang HW, Tseng CW, ChangChien CC: Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis. Gynecol Oncol; 2006 Mar;100(3):591-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of preoperative serum CA125 in early-stage adenocarcinoma of the uterine cervix without pelvic lymph node metastasis.
  • OBJECTIVE: This investigation attempted to clarify the value of preoperative serum CA125 in predicting histopathological prognostic factors for early-stage cervical adenocarcinoma without lymph node metastasis.
  • METHODS: This study initially surveyed 163 patients with clinical stage Ib or IIa cervical adenocarcinoma treated with radical hysterectomy and pelvic lymphadenectomy.
  • Multivariate analysis revealed that among the preoperative clinicopathological variables, including age, tumor size, parametrial invasion, and CA125 level, raised CA125 most significantly influenced the assessment of the LVSI (P = 0.040) and depth of cervical stromal invasion (P = 0.002).
  • CONCLUSIONS: In early-stage cervical adenocarcinoma with negative pelvic lymph node metastasis, preoperative serum CA125 levels at the cutoff value of 26 U/ml impacted the determination of the poor histopathological prognostic factors.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / pathology. CA-125 Antigen / blood. Uterine Cervical Neoplasms / blood. Uterine Cervical Neoplasms / pathology


23. Lin CK, Yu MH, Chu TW, Lai HC: Synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium. Taiwan J Obstet Gynecol; 2006 Dec;45(4):336-9
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium.
  • Patients with synchronous cervical and endometrial cancers are even rarer.
  • We describe a case of cervical squamous cell carcinoma and endometrial endometrioid adenocarcinoma occurring simultaneously in a 47-year-old woman presenting with massive menstrual bleeding.
  • Pelvic examination detected a large cervix but apparently normal externals.
  • Magnetic resonance imaging revealed a mass over the cervical region and endometrial lesions in the uterine cavity.
  • Surgical exploration disclosed a cervical tumor and erosion of the endometrium.
  • The pathologic findings were compatible with synchronous occurrence of primary neoplasms in the uterus with squamous cell carcinoma of the cervix and adenocarcinoma of the endometrium.
  • It is practical to pay more attention to the differential diagnosis of primary and metastatic tumors.
  • The second primary cancer that occurs in an individual with endometrial cancer may offer an opportunity for early detection.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Neoplasms, Multiple Primary / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Endometrial Neoplasms / diagnosis. Female. Humans. Lymphatic Metastasis / diagnosis. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175494.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


24. Chew GK, Cruickshank ME, Rooney PH, Miller ID, Parkin DE, Murray GI: Human papillomavirus 16 infection in adenocarcinoma of the cervix. Br J Cancer; 2005 Nov 28;93(11):1301-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus 16 infection in adenocarcinoma of the cervix.
  • The impact of the success of organised cervical screening programme results in a steady decline of the incidence of squamous cell carcinoma of the cervix but a concomitant increase in the incidence of the less common histological subtypes, particularly adenocarcinoma of the cervix (ACC).
  • Although Human papillomavirus (HPV) infection is believed to be a necessary cause of cervical cancer, its role in the pathogenesis of ACC is not well established.
  • In this study, the cervical adenocarcinoma cells of a 10-year cohort of women diagnosed with ACC were dissected using the PixCell II Laser Microdissecting System to detect the HPV 16 genome sequence using the real-time quantitative polymerase chain reaction to confirm the presence of HPV DNA within ACC cells.
  • [MeSH-major] Adenocarcinoma / virology. Human papillomavirus 16 / genetics. Human papillomavirus 16 / pathogenicity. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 1999 Jul;80 ( Pt 7):1725-33 [10423141.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Methods Mol Biol. 2005;293:27-37 [16028408.001]
  • [Cites] Lancet. 2000 Jun 24;355(9222):2194-8 [10881892.001]
  • [Cites] Mol Pathol. 2000 Apr;53(2):64-8 [10889904.001]
  • [Cites] Mod Pathol. 1998 Jan;11(1):11-8 [9556417.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2001 Oct;15(5):663-76 [11563866.001]
  • [Cites] Obstet Gynecol. 1980 Sep;56(3):361-4 [7422175.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 18;84(6):394-8 [1311392.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Lancet. 2001 May 12;357(9267):1490-3 [11377601.001]
  • (PMID = 16265348.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2361519
  •  go-up   go-down


25. Seles S, Lang GE: [CAR syndrome (carcinoma-associated retinopathy syndrome) associated with an adenocarcinoma of the cervix]. Klin Monbl Augenheilkd; 2005 Sep;222(9):736-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CAR syndrome (carcinoma-associated retinopathy syndrome) associated with an adenocarcinoma of the cervix].
  • [Transliterated title] CAR-Syndrom (carcinoma-associated retinopathy syndrome) assoziiert mit einem Adenokarzinom der Zervix.
  • Due to the patient's report about a resection of an adenocarcinoma of the cervix in June 2002, she was diagnosed as having CAR syndrome.
  • One has to take into consideration that visual dysfunction can appear before the primary cancer is diagnosed.
  • [MeSH-major] Adenocarcinoma / diagnosis. Paraneoplastic Polyneuropathy / diagnosis. Retinitis Pigmentosa / diagnosis. Uterine Cervical Neoplasms / diagnosis. Uveitis, Intermediate / diagnosis. Vision Disorders / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16175485.001).
  • [ISSN] 0023-2165
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Nola M, Tomicic I, Dotlic S, Morovic A, Petrovecki M, Jukic S: Adenocarcinoma of uterine cervix -- prognostic significance of clinicopathologic parameters. Croat Med J; 2005 Jun;46(3):397-403
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of uterine cervix -- prognostic significance of clinicopathologic parameters.
  • AIM: To investigate prognostic significance of several clinicopathologic parameters in patients with adenocarcinoma of the uterine cervix.
  • CONCLUSION: Our data showed that in patients with adenocarcinoma of the uterine cervix the nuclear grade, clinical stage, and architectural grade of the tumor represent the most important prognostic parameters.
  • [MeSH-major] Adenocarcinoma / mortality. Uterine Cervical Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861518.001).
  • [ISSN] 0353-9504
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


27. Kasamatsu T, Onda T, Sasajima Y, Kato T, Ikeda S, Ishikawa M, Tsuda H: Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix. Gynecol Oncol; 2009 Dec;115(3):488-92
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix.
  • OBJECTIVE: A retrospective analysis was carried out to evaluate the prognostic significance of peritoneal cytology in cervical adenocarcinoma.
  • METHODS: The records of 107 patients with FIGO stage IB to IIB cervical adenocarcinoma who underwent hysterectomy were reviewed.
  • Cox model analysis revealed positive cytology [hazards ratio (HR) 6.27, 95% confidence interval (CI) 2.13-18.41], positive lymph node (HR 6.20, 95% CI 1.87-20.57), ovarian metastasis (HR 5.20, 95% CI 1.18-22.82), and histological grade (HR 5.97, 95% CI 2.00-17.78) to be independent adverse risk factors for survival among the factors analyzed (lymph node status, lymph-vascular space invasion, tumor size, depth in cervical wall, pathological parametrial involvement, infiltration to vagina, ovarian metastasis, and histological grade).
  • CONCLUSION: The presence of positive peritoneal cytology appears to be an independent prognostic risk factor in patients with cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Peritoneal Cavity / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19767067.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Jaidane M, Slama A, Bibi M: A tumor of an ectopic ureter mimicking uterine cervix adenocarcinoma: case report and brief review. Int Urogynecol J Pelvic Floor Dysfunct; 2009 Nov;20(11):1393-5
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor of an ectopic ureter mimicking uterine cervix adenocarcinoma: case report and brief review.
  • We report the first case of an adenocarcinoma arising in an ectopic ureter in a woman and mimicking uterine cervical adenocarcinoma.
  • On gynecological exam, there were two cervixes with a small nodule on the left cervix.
  • After nodule biopsy, the initial diagnosis was adenocarcinoma of the uterine cervix.
  • Pelvic ultrasound and magnetic resonance imaging demonstrated an ectopic tumoral ureter draining a dysplastic pelvic kidney and inserted in the cervix of a bicornuate uterus.
  • Pathological exam demonstrated an adenocarcinoma arising in the ectopic ureter.
  • [MeSH-major] Adenocarcinoma / diagnosis. Choristoma / diagnosis. Ureter. Uterine Cervical Diseases / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Hysterectomy. Magnetic Resonance Imaging


29. Piketty M, Barranger E, Najat M, François P, Daraï E: Ovarian recurrence after radical trachelectomy for adenocarcinoma of the cervix. Am J Obstet Gynecol; 2005 Oct;193(4):1382-3
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian recurrence after radical trachelectomy for adenocarcinoma of the cervix.
  • Radical trachelectomy is an effective fertility-sparing treatment for women with early-stage cervical cancer.
  • We describe the first reported ovarian recurrence after radical trachelectomy for stage IB1 adenocarcinoma cervical cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Cervix Uteri / surgery. Neoplasms, Second Primary. Ovarian Neoplasms / secondary. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery. Uterus / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Obstet Gynecol. 2007 Feb;196(2):e22; author reply e22-3 [16959199.001]
  • (PMID = 16202730.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Abhishek A, Ouseph MM, Sharma P, Kamal V, Sharma M: Bulky scalp metastasis and superior sagittal sinus thrombosis from a cervical adenocarcinoma: an unusual case. J Med Imaging Radiat Oncol; 2008 Feb;52(1):91-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bulky scalp metastasis and superior sagittal sinus thrombosis from a cervical adenocarcinoma: an unusual case.
  • Distant cutaneous metastases from cervical malignancies are uncommon, with scalp metastases being exceptional events.
  • We present the case of a 53-year-old postmenopausal lady with adenocarcinoma of the uterine cervix that metastasized to the scalp with superior sagittal sinus thrombosis 8 months after diagnosis.
  • In contrast to the seven prior cases of scalp metastases of cervical squamous cell carcinoma reported in published reports, ours is the first documentation of such an occurrence in cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Head and Neck Neoplasms / secondary. Scalp / pathology. Sinus Thrombosis, Intracranial / etiology. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Cervix Uteri / radiography. Cervix Uteri / surgery. Epilepsy, Tonic-Clonic / drug therapy. Epilepsy, Tonic-Clonic / etiology. Female. Humans. Hysterectomy. Magnetic Resonance Imaging / methods. Middle Aged. Tomography, X-Ray Computed / methods


31. Missaoui N, Hmissa S, Frappart L, Trabelsi A, Ben Abdelkader A, Traore C, Mokni M, Yaacoubi MT, Korbi S: p16INK4A overexpression and HPV infection in uterine cervix adenocarcinoma. Virchows Arch; 2006 May;448(5):597-603
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16INK4A overexpression and HPV infection in uterine cervix adenocarcinoma.
  • Human papillomaviruses (HPVs) are causally involved in the genesis of cervical carcinomas and their precursors, and there is a strong relationship between the cyclin-dependant kinase inhibitor p16INK4A and HPV infection.
  • This study was carried out to assess the correlations between p16INK4A expression as an early biomarker of the endocervical adenocarcinoma and HPV infection. p16INK4A expression and HPV typing were performed on 46 samples including 5 normal endocervix, 9 benign lesions of the endocervix, 25 endocervical adenocarcinomas, and 7 endometrioid adenocarcinomas of the uterine corpus.
  • All of the 25 endocervical adenocarcinomas overexpressed p16INK4A; the adjacent epithelium and the connective tissue were strictly negative.
  • Few endometrioid adenocarcinomas of the uterine corpus that infiltrate the endocervix exhibited a low immunoreactivity (score 0/15 or 1/15).
  • Our results suggest that p16INK4A is a putative molecular biomarker that consistently discriminates uterine cervix adenocarcinomas from benign lesions and from endometrioid adenocarcinomas of the uterine corpus.
  • [MeSH-major] Adenocarcinoma / virology. Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Papillomavirus Infections / complications. Tumor Virus Infections / complications. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Annu. 1973;8:301-28 [4583016.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):42-55 [11237522.001]
  • [Cites] EMBO J. 1995 Feb 1;14(3):503-11 [7859739.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Pathol Int. 1995 Jul;45(7):506-12 [7551011.001]
  • [Cites] J Pathol. 2003 Dec;201(4):535-43 [14648656.001]
  • [Cites] Virus Res. 2002 Nov;89(2):213-28 [12445661.001]
  • [Cites] FASEB J. 2000 Aug;14(11):1585-94 [10928993.001]
  • [Cites] Biochim Biophys Acta. 1996 Oct 9;1288(2):F55-78 [8876633.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1055-62 [11021808.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):55-61 [10502426.001]
  • [Cites] Int J Cancer. 2004 Apr 10;109(3):317-21 [14961567.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):1-3 [11781515.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):827-41 [10074914.001]
  • [Cites] Am J Pathol. 1990 Sep;137(3):659-66 [2169191.001]
  • [Cites] Br J Cancer. 1997;75(10):1410-6 [9166931.001]
  • [Cites] J Virol. 2004 Oct;78(20):11172-86 [15452237.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jul;22(3):231-5 [12819388.001]
  • [Cites] Annu Rev Microbiol. 1994;48:427-47 [7826013.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):884-91 [11420459.001]
  • [Cites] Int J Gynaecol Obstet. 1998 Dec;63(3):265-70 [9989896.001]
  • [Cites] Cancer. 2001 Feb 25;93(1):8-15 [11241260.001]
  • [Cites] Anticancer Res. 1991 Jan-Feb;11(1):123-7 [1850213.001]
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):71-5 [9495362.001]
  • [Cites] Am J Clin Pathol. 1996 Jul;106(1):52-6 [8701932.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] Hum Pathol. 1998 Oct;29(10):1035-8 [9781637.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1389-99 [12409715.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):439-45 [10831356.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] J Virol. 1988 May;62(5):1659-66 [2833616.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):246-50 [11166153.001]
  • [Cites] Int J Gynecol Pathol. 2003 Oct;22(4):378-85 [14501820.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):187-93 [12548164.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] J Virol Methods. 1991 Nov-Dec;35(2):143-57 [1667785.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):689-96 [15188135.001]
  • [Cites] Virchows Arch. 2001 Jul;439(1):55-61 [11499840.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):4-10 [11781516.001]
  • [Cites] Yonsei Med J. 2002 Dec;43(6):722-8 [12497655.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):665-73 [12861062.001]
  • [Cites] Hum Pathol. 2002 Sep;33(9):899-904 [12378514.001]
  • [Cites] Am J Obstet Gynecol. 2004 Mar;190(3):668-73 [15041997.001]
  • [Cites] Mol Cell Endocrinol. 1996 Jan 15;116(1):115-9 [8822272.001]
  • (PMID = 16496173.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


32. Pradhan D, Pattnaik K, Pahi J, Mohanty P, Satpathy S, Behuria S: Adenoid cystic carcinoma in the uterine cervix: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):1039-42
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma in the uterine cervix: a case report.
  • BACKGROUND: Adenoid cystic carcinoma, a variant of adenocarcinoma of the uterine cervix, is an extremely rare neoplasm.
  • This report describes a case of primary adenoid cystic carcinoma of the uterine cervix and includes the cytopathologic and histopathologic findings.
  • Speculum examination showed a firm mass in the uterine cervix.
  • The diagnosis of adenoid cystic carcinoma was confirmed by the histopathologic examination of the biopsy specimen as well as the excised specimen, which characteristically revealed the presence of a cribriform pattern of the tumor cells.
  • CONCLUSION: We reported a case of a rare and unusual variant of adenocarcinoma of the uterine cervix by considering the characteristic cytologic features of the globules of pale, translucent material surrounded by halos of cells in cribriform adenoid cystic carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053595.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Macdonald RD, Kirwan J, Hayat K, Herrington CS, Shawki H: Villoglandular adenocarcinoma of the cervix: clarity is needed on the histological definition for this difficult diagnosis. Gynecol Oncol; 2006 Jan;100(1):192-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular adenocarcinoma of the cervix: clarity is needed on the histological definition for this difficult diagnosis.
  • BACKGROUND: Villoglandular adenocarcinoma (VGA) of the cervix is reported as a variant of a cervical adenocarcinoma with a good prognosis.
  • CASES: We present two cases histologically reported as a villoglandular adenocarcinoma of the cervix that have recurred and progressed rapidly since initial treatment.
  • External histopathological review suggested both had a prominent villoglandular pattern but with an associated underlying well-differentiated adenocarcinoma.
  • CONCLUSION: The diagnosis of VGA is difficult.
  • Because of the rarity of VGA and the difficulty but importance of the diagnosis, we would feel that a central review of all cases of VGA is warranted.
  • This would assist in diagnosis and also in obtaining accurate follow-up data.
  • [MeSH-major] Adenocarcinoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology


34. Yamauchi N, Sameshima H, Osato K, Fukushima K, Sato Y, Ikenoue T: Carcinomatous meningitis from adenocarcinoma of the uterine cervix: a case report and literature review. J Obstet Gynaecol Res; 2010 Apr;36(2):444-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinomatous meningitis from adenocarcinoma of the uterine cervix: a case report and literature review.
  • Carcinomatous meningitis from uterine cervix-related malignancies is a rare complication.
  • We found only eight cases of meningeal metastasis from primary cervical carcinoma in the English-language medical literature.
  • Thus, the clinical signs and methods for diagnosis are of great importance.
  • A 47-year-old Japanese woman had a stage IIIb uterine cervical adenocarcinoma.
  • We performed a lumbar puncture, which demonstrated adenocarcinoma cells compatible with metastases from the primary cervical adenocarcinoma.
  • This rare complication occurs in the advanced stage of cervical cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Meningeal Carcinomatosis / secondary. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20492405.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


35. Bray F, Carstensen B, Møller H, Zappa M, Zakelj MP, Lawrence G, Hakama M, Weiderpass E: Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev; 2005 Sep;14(9):2191-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence trends of adenocarcinoma of the cervix in 13 European countries.
  • Rapid increases in cervical adenocarcinoma incidence have been observed in Western countries in recent decades.
  • Postulated explanations include an increasing specificity of subtype-the capability to diagnose the disease, an inability of cytologic screening to reduce adenocarcinoma, and heterogeneity in cofactors related to persistent human papillomavirus infection.
  • Age-period-cohort models were fitted to cervical adenocarcinoma incidence trends in women ages <75 in 13 European countries.
  • Age-adjusted adenocarcinoma incidence rates increased throughout Europe, the rate of increase ranging from around 0.5% per annum in Denmark, Sweden, and Switzerland to >/=3% in Finland, Slovakia, and Slovenia.
  • Whereas increasing specificity of subtype with time may be responsible for some of the increases in several countries, the changing distribution and prevalence of persistent infection with high-risk human papillomavirus types, alongside an inability to detect cervical adenocarcinoma within screening programs, would accord with the temporal profile observed in Europe.
  • The homogeneity of trends in adenocarcinoma and squamous cell carcinoma in birth cohort is consistent with the notion that they share a similar etiology irrespective of the differential capability of screen detection.
  • Screening may have had at least some impact in reducing cervical adenocarcinoma incidence in several countries during the 1990s.
  • [MeSH-major] Adenocarcinoma / epidemiology. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16172231.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


36. Niibe Y, Hayakawa K, Kanai T, Tsunoda S, Arai M, Jobo T, Kuramoto H, Unno N: Optimal dose for stage IIIB adenocarcinoma of the uterine cervix on the basis of biological effective dose. Eur J Gynaecol Oncol; 2006;27(1):47-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal dose for stage IIIB adenocarcinoma of the uterine cervix on the basis of biological effective dose.
  • PURPOSE: Prognosis of uterine cervical adenocarcinoma in locally advanced stage treated with radiation therapy has been considered to be much worse than that of squamous cell carcinoma because the optimal dose for the former one has not been determined.
  • Thus, the current study was performed to investigate the optimal dose for Stage IIIB, locally advanced stage, adenocarcinoma of the uterine cervix on the basis of the biological effective dose (BED).
  • METHODS: One-hundred and seventy-nine patients with Stage IIIB carcinoma of the uterine cervix were treated with curative intended therapy at Kitasato University Hospital between 1976 and 2000.
  • Out of them, 13 patients had an adenocarcinoma component in pathological findings.
  • Nine patients were diagnosed with adenocarcinoma and four patients were diagnosed with adenosquamous cell carcinoma.
  • CONCLUSION: The current study suggested that the optimal dose for Stage IIIB adenocarcinoma of the uterine cervix might be T-BED10 > or = 100 Gy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Radiotherapy, High-Energy / methods. Salvage Therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550968.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


37. Yahata T, Numata M, Kashima K, Sekine M, Fujita K, Yamamoto T, Tanaka K: Conservative treatment of stage IA1 adenocarcinoma of the cervix during pregnancy. Gynecol Oncol; 2008 Apr;109(1):49-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative treatment of stage IA1 adenocarcinoma of the cervix during pregnancy.
  • OBJECTIVE: The incidence of glandular neoplasms of the uterine cervix has been steadily increasing over the past 2 decades.
  • Few reports have described the treatment of glandular neoplasms of the cervix in gravid women.
  • This report describes the preliminary results of treating stage IA1 cervical adenocarcinoma by cervical conization during pregnancy.
  • METHODS: All patients diagnosed to have FIGO stage IA1 cervical adenocarcinoma between 1990 and 2006 were reviewed and patients diagnosed during pregnancy were identified.
  • RESULTS: Sixteen patients with stage IA1 cervical adenocarcinoma were identified.
  • The histology showed that all of the tumors were endocervical type adenocarcinoma.
  • Two patients had positive conization margins for invasive cancer and underwent a second conization at 20 weeks' gestation and 5 weeks after delivery, respectively.
  • One patient was treated with cervical conization alone and 3 patients were treated with an extended radical hysterectomy with pelvic lymph nodes dissection after delivery.
  • No patient had residual invasive cancer in a subsequent surgical specimen.
  • CONCLUSION: These preliminary data suggest that patients with FIGO stage IA1 cervical adenocarcinoma may be treated conservatively by cervical conization during pregnancy.
  • [MeSH-major] Adenocarcinoma / surgery. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery


38. Swartz RJ, West LA, Boiko I, Malpica A, Guillaud M, Macaulay C, Follen M, Atkinson EN, Cox DD: Classification using the cumulative log-odds in the quantitative pathologic diagnosis of adenocarcinoma of the cervix. Gynecol Oncol; 2005 Dec;99(3 Suppl 1):S24-31
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification using the cumulative log-odds in the quantitative pathologic diagnosis of adenocarcinoma of the cervix.
  • The method was tested using data from cervical adenocarcinomas, adenocarcinoma in situ, and normal columnar tissue.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Logistic Models. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology


39. Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, Nishimura R: Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol; 2007 May;31(5):664-72
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix.
  • Endocervical-type mucinous adenocarcinoma (ECA) of the uterine cervix is defined as a tumor composed of cells resembling those of the endocervical glands, but recent studies have demonstrated that a minority of ECAs displays a gastric immunophenotype.
  • Fifty-three cases of mucinous adenocarcinoma of the uterine cervix (37 FIGO stage IB, 4 stage IIA, and 12 stage IIB) were reviewed and reevaluated using a newly established morphologic criteria for distinguishing gastric type adenocarcinoma, which was defined as a tumor showing clear and/or pale eosinophilic and voluminous cytoplasm, with distinct cell borders.
  • Following the current World Health Organization scheme (2003), 47 tumors (89%) were classified as ECA, 1 (2%) as intestinal type, 1 (2%) as mixed endocervical and intestinal type, and 4 (8%) as minimal deviation adenocarcinoma.
  • Twelve of 47 (26%) ECAs and all 4 minimal deviation adenocarcinomas, reclassified as gastric type using the novel criteria, were frequently positive for HIK1083 with a rate of 75% (12/16), whereas only 11% (4/37) of nongastric tumors were positive.
  • Patients with gastric-type adenocarcinomas had a significantly decreased 5-year disease-specific survival rate (30 vs. 77%; P<0.0001), and the gastric type morphology was related to a significant risk for disease recurrence compared with the nongastric type (P=0.001; HR, 4.5; 95% confidence interval, 1.42-14.2).
  • Mucinous adenocarcinoma of the uterine cervix with gastric immunophenotype can be a distinct morphologic variant showing an aggressive clinical course.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Gastric Mucosa / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460448.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Gastric Mucins
  •  go-up   go-down


40. Yao JF, Zhou CY, Wei LF, Wang SY, Shi YF: [Expression of aquaporin-8 and bcl-2 protein in human cervical carcinoma and their correlations]. Zhonghua Fu Chan Ke Za Zhi; 2008 Mar;43(3):205-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of aquaporin-8 and bcl-2 protein in human cervical carcinoma and their correlations].
  • OBJECTIVE: To investigate the expression of aquaporin-8 (AQP8) and apoptosis associated bcl-2 protein in human cervical carcinoma and their relationship.
  • METHODS: The expression of AQP8 and bcl-2 protein in 74 cases of cervical carcinoma (46 cases of squamous-cell carcinoma of the uterine cervix, 28 cases of adenocarcinoma of the uterine cervix), 34 cases of cervical intraepithelial neoplasia (CIN) and 15 cases of normal cervices were detected by immunohistochemical technique, and their clinical significance were analyzed.
  • RESULTS: The expression of AQP8 and bcl-2 protein were detected in intracytoplasm of atypia cells in CIN, squamous-cell carcinoma and adenocarcinoma of the uterine cervix.
  • The positive rates of AQP8 and bcl-2 in squamous-cell carcinoma, adenocarcinoma, CIN and normal cervical epithelium were 98%, 74%; 61%, 71%; 71%, 53% ; 53%, 20% respectively.
  • There were significant differences between squamous-cell carcinoma of the uterine cervix and other groups in AQP8 (P < 0.01), but no significant differences were found in any other groups.
  • There were significant differences between squamous-cell carcinoma of the uterine cervix and CIN or normal cervical epithelium in bcl-2, so were between adenocarcinoma of the uterine cervix.
  • The expression of AQP8 was positively correlated with bcl-2 in human cervical carcinoma( r(s) = 0.463, P = 0.000).
  • CONCLUSIONS: There is a close relationship between high expression of AQP8 and development of human cervical carcinoma.
  • The expression of AQP8 protein is positively correlated with bcl-2 protein in human cervical carcinoma.
  • AQP8 protein may have anti-apoptosis function, although the detailed mechanism in human cervical carcinoma remains to be clarified.
  • [MeSH-major] Aquaporins / metabolism. Carcinoma, Squamous Cell / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Cervix Uteri / metabolism. Cervix Uteri / pathology. Down-Regulation. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788571.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Aquaporins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / aquaporin 8
  •  go-up   go-down


41. Niibe Y, Kenjo M, Onishi H, Ogawa Y, Kazumoto T, Ogino I, Tsujino K, Harima Y, Takahashi T, Anbai A, Tsuchida E, Toita T, Takemoto M, Yamashita H, Hayakawa K: High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in Japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006-2007 (study of JASTRO 2006-2007). Jpn J Clin Oncol; 2010 Aug;40(8):795-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in Japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006-2007 (study of JASTRO 2006-2007).
  • OBJECTIVE: The current study was a retrospective questionnaire survey of stage IIIb adenocarcinoma of the uterine cervix treated with high-dose-rate intracavitary brachytherapy combined with external beam radiation therapy in Japan aimed to investigate the optimal dose on the basis of the biological effective dose and prognostic factors.
  • METHODS: Between 1990 and 2000, 61 patients with stage IIIb adenocarcinoma of the uterine cervix underwent high-dose-rate intracavitary brachytherapy combined with external beam radiation therapy in 19 major hospitals in Japan.
  • Fifty had only adenocarcinoma components and 11 had adenosquamous cell carcinoma components.
  • Stratified by histopathology, the 5-year overall survival rate was 22.1% for adenocarcinoma and 13.6% for adenosquamous cell carcinoma (P = 0.43).
  • CONCLUSIONS: The 5-year overall survival rate of stage IIIb adenocarcinoma of the uterine cervix in this retrospective questionnaire survey was 20.2%.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Carcinoma, Adenosquamous / radiotherapy. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20444747.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


42. Yabushita H, Kanyama K, Sekiya R, Noguchi M, Wakatsuki A: Clear-cell adenocarcinoma of the uterine cervix in a 17-year-old adolescent. Int J Clin Oncol; 2008 Dec;13(6):552-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear-cell adenocarcinoma of the uterine cervix in a 17-year-old adolescent.
  • This report describes the case of the youngest Japanese person to be diagnosed with endocervical clearcell adenocarcinoma.
  • A cervical tumor was discovered, and the patient was referred to our outpatient department.
  • Vaginal examination showed a bleeding tumor approximately 1.5 cm in size protruding from the cervical os.
  • The cytological finding of the uterine cervix was positive for malignancy, and the histological diagnosis by punch biopsy was clear-cell adenocarcinoma of the uterine cervix.
  • Macroscopic findings showed a tumor, 1.5 cm in diameter, growing from the right side of the uterine cervix.
  • The pathological diagnosis was clear-cell adenocarcinoma of the cervix (PT1b1NR0M0).
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1970 Apr;25(4):745-57 [5443099.001]
  • [Cites] Int J Clin Oncol. 2003 Dec;8(6):399-404 [14663645.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2229-36 [9179071.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1055-62 [11021808.001]
  • [Cites] Obstet Gynecol. 1974 May;43(5):640-4 [4822647.001]
  • [Cites] N Engl J Med. 1971 Aug 12;285(7):390-2 [5556578.001]
  • [Cites] Semin Diagn Pathol. 1997 Nov;14(4):233-9 [9383823.001]
  • [Cites] N Engl J Med. 1971 Apr 15;284(15):878-81 [5549830.001]
  • [Cites] Br Med J. 1978 Jun 17;1(6127):1588-90 [656822.001]
  • [Cites] N Engl J Med. 1987 Feb 26;316(9):514-6 [3807995.001]
  • [Cites] J Reprod Med. 1983 Feb;28(2):137-46 [6834354.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):507-13 [8630958.001]
  • [Cites] Obstet Gynecol. 1973 Apr;41(4):494-500 [4696964.001]
  • (PMID = 19093185.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


43. Andersson S, Hellström AC, Angström T, Stendahl U, Auer G, Wallin KL: The clinicopathologic significance of laminin-5 gamma2 chain expression in cervical squamous carcinoma and adenocarcinoma. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1065-72
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathologic significance of laminin-5 gamma2 chain expression in cervical squamous carcinoma and adenocarcinoma.
  • Carcinoma of the uterine cervix is one of the most prevalent malignancies among women in developing countries and the third most common type worldwide.
  • Squamous cell carcinoma predominates in the cervix uteri, while adenocarcinoma and adenosquamous carcinomas represent about 10-15% of all cervical cancers.
  • Many studies have confirmed that the human papillomavirus (HPV) is the most important etiologic factor in the development of cervical cancer.
  • The aim of our study was to investigate the expression of the laminin-5 gamma2 chain in primary malignancies of the cervix uteri and to focus on the clinicopathologic significance of the expression of the laminin-5 gamma2 chain in cervical squamous carcinoma and adenocarcinoma with respect to age and survival of the patients.
  • The study consisted of a total of 89 cases of invasive cervical cancer (54 squamous carcinomas and 35 adenocarcinomas).
  • The laminin-5 gamma2 chain was found in 80% of all the squamous carcinoma and in 66% of cervical adenocarcinoma.
  • The univariate analysis in squamous cell carcinoma showed that factors such as the stage of the disease and positive lymph nodes had an impact on the survival of the patients, whereas in the multivariate analysis, only age at diagnosis was an independent prognostic factor.
  • However, in cases with cervical adenocarcinoma, only the stage of the disease was an independent prognostic factor.
  • Our results indicate that the majority of the primary cervical tumors, especially squamous cell carcinoma, showed expression of laminin-5 gamma2 chain immunoreactivity.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Laminin / biosynthesis. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343183.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LAMC2 protein, human; 0 / Laminin
  •  go-up   go-down


44. Sasieni P, Castanon A, Cuzick J: Screening and adenocarcinoma of the cervix. Int J Cancer; 2009 Aug 1;125(3):525-9
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening and adenocarcinoma of the cervix.
  • Screening has had a major impact on cervical cancer in many countries.
  • Although there can be no doubt about its effectiveness in preventing squamous-cell carcinoma, there is little evidence of any benefit on adenocarcinoma and adenosquamous carcinoma of the cervix, and many authors have concluded that it is ineffective.
  • Among 3,305 cases with known histology, 641 had adenocarcinoma and 133 adenosquamous carcinoma.
  • The risk reduction associated with 3-yearly screening was greater for squamous carcinoma (75%, 95%CI 71-79%) and adenosquamous carcinoma (83%, 95%CI 68-91%) than for adenocarcinoma (43%, 95%CI 24-58%).
  • Among stage 1B+ cases, 83% (335/406) of women with adenocarcinoma had been screened within 10 years of diagnosis.
  • Incidence of adenocarcinoma was low within 2.5 years of a negative smear (OR 2.3, 95%CI 0.15-0.34), but was no different from the background rates 4.5-5.5 years after a negative smear.
  • We conclude that screening has reduced the incidence of adenocarcinoma of the cervix, but the prognostic value of cytology is less (in both magnitude and duration) for adenocarcinoma than for squamous carcinoma.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / prevention & control. Carcinoma, Adenosquamous / epidemiology. Carcinoma, Adenosquamous / prevention & control. Mass Screening. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / prevention & control


45. Srilatha PS, Roy A: Villoglandular papillary adenocarcinoma of cervix associated with cervical intraepithelial neoplasia: a case report and review of literature. Indian J Pathol Microbiol; 2007 Oct;50(4):819-21
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of cervix associated with cervical intraepithelial neoplasia: a case report and review of literature.
  • Well differentiated villoglandular adenocarcinoma of uterine cervix is a rare tumour which usually occurs in young women.
  • Physical examination revealed a cervical polyp.
  • Histopathological findings were consistent with villoglandular papillary adenocarcinoma associated with high grade cervical intraepithelial neoplasia (CIN-3).
  • [MeSH-major] Adenocarcinoma, Papillary / complications. Adenocarcinoma, Papillary / pathology. Cervical Intraepithelial Neoplasia / complications. Cervical Intraepithelial Neoplasia / pathology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adnexa Uteri / pathology. Adult. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Female. Humans. Hydronephrosis. Polyps. Ureter / pathology


46. Poujade O, Morice P, Rouzier R, Madelenat P, Lecuru F, Muray JM, Mathevet P, Alran S, Salmon RJ, Reyal F: Pathologic response rate after concomitant neo-adjuvant radiotherapy and chemotherapy for adenocarcinoma of the uterine cervix: a retrospective multicentric study. Int J Gynecol Cancer; 2010 Jul;20(5):815-20
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic response rate after concomitant neo-adjuvant radiotherapy and chemotherapy for adenocarcinoma of the uterine cervix: a retrospective multicentric study.
  • INTRODUCTION: Exclusive chemoradiotherapy (including brachytherapy) is the current standard of care for locoregionally advanced cervical cancer.
  • The aim of the present study was to evaluate the responsiveness and to identify factors predicting the response to concomitant chemoradiotherapy before surgery in cervical adenocarcinoma.
  • A total of 54 women with cervical adenocarcinoma stage IB2 to IIIB who had undergone concurrent chemoradiation therapy followed by surgical treatment were included.
  • RESULTS: The median (SD) age at diagnosis was 44.2 (12.4) years (range, 19.3-77 years).
  • CONCLUSIONS: Identification of predictive markers associated with incomplete response to neoadjuvant chemoradiotherapy in cervical adenocarcinoma may prove clinically useful and implement an individualized treatment plan.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Gynecologic Surgical Procedures. Radiotherapy, Adjuvant. Uterine Cervical Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20606528.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


47. Faried LS, Faried A, Kanuma T, Aoki H, Sano T, Nakazato T, Tamura T, Kuwano H, Minegishi T: Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy. Mol Carcinog; 2008 Jun;47(6):446-57
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy.
  • Alterations of the Akt/mTOR pathway have been observed in numerous types of cancer, thus this pathway represents an exciting new target for molecular therapeutics.
  • We investigated the expression of activated Akt (p-Akt) and mTOR (p-mTOR) in patients with adenocarcinoma of the cervix and the involvement of the p-Akt/p-mTOR pathway in response to combination of inhibitor agents, rapamycin and LY294002, with conventional therapy, cisplatin, in vitro.
  • Immunohistochemistry analysis of p-Akt and p-mTOR was conducted in 26 patients with adenocarcinoma of the cervix.
  • Western blot analysis was performed to determine the protein expression involved in response to chemotherapy in cervical cancer cell lines.
  • The results showed that p-Akt and p-mTOR were identified in 50% and 53.8% of adenocarcinoma of the cervix.
  • Overall, the expression of p-mTOR is a significant prognostic marker of adenocarcinoma of the cervix and a potential molecular target for the treatment of cervical cancer.
  • Inhibition of the mTOR pathway contributes to cisplatin-induced apoptosis in cervical cancer cell lines.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Protein Kinases / metabolism. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18058806.001).
  • [ISSN] 1098-2744
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


48. Hamer OW, Flint J, Ryan CF, Manos D, Müller NL: Mucoid impaction secondary to mucin-producing metastatic adenocarcinoma of the cervix. Br J Radiol; 2008 Aug;81(968):e201-3
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoid impaction secondary to mucin-producing metastatic adenocarcinoma of the cervix.
  • Here, we describe an uncommon case of endobronchial metastasis of adenocarcinoma of the cervix causing mucoid impaction owing to mucous production by the tumour cells.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Bronchial Neoplasms / secondary. Uterine Cervical Neoplasms

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628324.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


49. Lin YW, Chung MT, Lai HC, De Yan M, Shih YL, Chang CC, Yu MH: Methylation analysis of SFRP genes family in cervical adenocarcinoma. J Cancer Res Clin Oncol; 2009 Dec;135(12):1665-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation analysis of SFRP genes family in cervical adenocarcinoma.
  • Recently, we have shown that secreted frizzled-related proteins (SFRPs) are frequently methylated in cervical squamous cell carcinoma (SCC).
  • Here, we want to further investigate the methylation status and function of SFRPs in adenocarcinoma of uterine cervix.
  • METHODS: The methylation status of SFRPs was assessed in 23 adenocarcinomas (AC), and 45 normal control swabs by methylation-specific polymerase chain reaction and bisulfite sequencing.
  • Then, we used reexpression of SFRP5 in cervical cancer cell lines, HeLa3rd and CaSki, to study the role of SFRP5 in cervical adenocarcinoma by colony formation and invasion assays.
  • RESULTS: The frequency of SFRP genes promoter hypermethylation in adenocarcinoma of cervix samples was 52.2% (12/23), 82.6% (19/23), 65.2% (15/23), and 73.9% (17/23), for SFRP1, SFRP2, SFRP4, and SFRP5, respectively.
  • The frequency of SFRP1, SFRP2, SFRP4, and SFRP5 promoter methylation in adenocarcinoma was significantly higher than in normal control samples (P < 0.001).
  • CONCLUSIONS: Our data suggest that promoter hypermethylation of SFRPs is associated with cervical adenocarcinoma, which could be used for molecular screening of cervical adenocarcinoma in the future.
  • Moreover, SFRP5 inhibits cervical tumorigenesis through interfering Wnt pathway in vitro.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Methylation. Membrane Proteins / genetics. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1992 Jan;44(1):71-8 [1730429.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] Carcinogenesis. 2008 May;29(5):991-8 [18356147.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):646-53 [19095296.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6770-5 [9192640.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2007 Dec;47(6):504-7 [17991118.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):883-8 [14871816.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1784-7 [9065401.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):536-45 [9466653.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6672-6 [15221014.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):687-92 [11257100.001]
  • [Cites] Genes Dev. 2000 Aug 1;14 (15):1837-51 [10921899.001]
  • [Cites] Nature. 2001 Jul 5;412(6842):86-90 [11452312.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Mar;36(3):233-41 [12557223.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3396-400 [15161694.001]
  • [Cites] Cancer. 2006 Aug 1;107(3):579-90 [16795071.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1996 Mar;65(1):45-53 [8706956.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):163-7 [9988266.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2109-16 [16609023.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Apr;94(2):151-2 [9109947.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Genes Dev. 1997 Dec 15;11(24):3286-305 [9407023.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1028-35 [17443492.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2981-4 [12912945.001]
  • [Cites] J Med Screen. 1997;4(1):40-3 [9200062.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Trends Genet. 2000 Apr;16(4):168-74 [10729832.001]
  • [Cites] J Pathol. 2002 Jan;196(1):1-7 [11748635.001]
  • [Cites] Int J Gynecol Cancer. 2002 Mar-Apr;12(2):171-6 [11975676.001]
  • [Cites] Ann Intern Med. 2000 May 16;132(10):810-9 [10819705.001]
  • [Cites] Gynecol Oncol. 2009 Feb;112(2):301-6 [19038436.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 16;97(4):273-82 [15713962.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3546-51 [10097073.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1790-2 [9065403.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):97-105 [10926787.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1258-64 [15693030.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):161-7 [18398837.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):67-70 [9892187.001]
  • [Cites] Gynecol Oncol. 2007 Mar;104(3):629-35 [17097722.001]
  • (PMID = 19513747.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Eye Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / SFRP1 protein, human; 0 / SFRP5 protein, human
  •  go-up   go-down


50. Kang S, Kim MH, Park IA, Kim JW, Park NH, Kang D, Yoo KY, Kang SB, Lee HP, Song YS: Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix. Cancer Lett; 2006 Jun 18;237(2):305-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of cyclooxygenase-2 is related to lymph node metastasis in adenocarcinoma of uterine cervix.
  • In a previous study, we demonstrated that elevation of COX-2 is significantly associated with lymph node metastasis in squamous cell carcinoma (SCC) of cervix.
  • The main objective of this study is to characterize the relationship between elevation of COX-2 and its possible clinical role in adenocarcinoma (AC) of cervix.
  • Using immunohistochemistry, we examined COX-2 expression levels in 84 patients with AC of uterine cervix [71 ACs, 13 adenosquamous carcinomas (ASCs)].
  • The present study shows that elevation of COX-2 may contribute to lymph node metastasis in AC of uterine cervix.
  • This suggests that the potential therapeutic role of COX-2 inhibitors should be validated, not only in SCC, but also in AC of uterine cervix.
  • [MeSH-major] Adenocarcinoma / pathology. Cyclooxygenase 2 / biosynthesis. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Uterine Cervical Neoplasms / pathology


51. Poynor EA, Marshall D, Sonoda Y, Slomovitz BM, Barakat RR, Soslow RA: Clinicopathologic features of early adenocarcinoma of the cervix initially managed with cervical conization. Gynecol Oncol; 2006 Dec;103(3):960-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of early adenocarcinoma of the cervix initially managed with cervical conization.
  • OBJECTIVE: To evaluate the clinicopathologic features of microinvasive adenocarcinoma of the cervix in order to guide the management of patients with this disease.
  • MATERIALS AND METHODS: A retrospective review was conducted of patients diagnosed with early invasive, <or=5 mm stromal invasion, adenocarcinoma of the cervix by a cervical conization between 1992 and 1999 at our institution.
  • Ten patients had positive conization margins for invasive cancer, 3 patients had margins positive for adenocarcinoma in situ, 14 patients had negative margins, and in 6 patients the margin status could not be evaluated.
  • CONCLUSIONS: Historically, the standard management of early invasive adenocarcinoma of the cervix has been controversial, and some clinicians continue to favor radical treatments.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / surgery. Conization / utilization. Outcome Assessment (Health Care). Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860853.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Bulk S, Berkhof J, Bulkmans NW, Zielinski GD, Rozendaal L, van Kemenade FJ, Snijders PJ, Meijer CJ: Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer; 2006 Jan 16;94(1):171-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands.
  • We present the type-distribution of high-risk human papillomavirus (HPV) types in women with normal cytology (n=1467), adenocarcinoma in situ (ACIS) (n=61), adenocarcinoma (n=70), and squamous cell carcinoma (SCC) (n=83).
  • Cervical adenocarcinoma and ACIS were significantly more frequently associated with HPV18 (OR(MH) 15.0; 95% CI 8.6-26.1 and 21.8; 95% CI 11.9-39.8, respectively) than normal cytology.
  • Human papillomavirus16 was only associated with adenocarcinoma and ACIS after exclusion of HPV18-positive cases (OR(MH) 6.6; 95% CI 2.8-16.0 and 9.4; 95% CI 2.8-31.2, respectively).
  • These results suggest that HPV18 is mainly a risk factor for the development of adenocarcinoma whereas HPV16 is associated with both SCC and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / etiology. Adenocarcinoma / virology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / virology. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / etiology. Uterine Cervical Neoplasms / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Nov;36(17):2244-6 [11072213.001]
  • [Cites] Int J Cancer. 2005 Nov 1;117(2):177-81 [15900579.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jan-Feb;11(1):39-48 [11285032.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):398-404 [11487272.001]
  • [Cites] J Clin Microbiol. 2002 Mar;40(3):779-87 [11880393.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] Lancet. 2003 Jan 4;361(9351):40-3 [12517465.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):63-73 [12556961.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Am J Obstet Gynecol. 2003 Mar;188(3):657-63 [12634637.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):101-5 [12838308.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7215-20 [14612516.001]
  • [Cites] J Pathol. 2003 Dec;201(4):535-43 [14648656.001]
  • [Cites] Lancet. 2003 Dec 6;362(9399):1871-6 [14667741.001]
  • [Cites] J Clin Virol. 2004 Apr;29(4):271-6 [15018855.001]
  • [Cites] J Clin Pathol. 2004 Apr;57(4):388-93 [15047743.001]
  • [Cites] Int J Cancer. 2004 May 20;110(1):94-101 [15054873.001]
  • [Cites] Int J Epidemiol. 1995 Apr;24(2):300-7 [7635589.001]
  • [Cites] J Clin Microbiol. 1997 Mar;35(3):791-5 [9041439.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):268-75 [15688404.001]
  • [Cites] J Infect Dis. 2005 Jun 1;191(11):1808-16 [15871112.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1157-64 [15894666.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1066-71 [16030304.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9 [16030305.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1906-15 [11283122.001]
  • (PMID = 16404371.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361088
  •  go-up   go-down


53. Shintaku M, Kushima R, Abiko K: Colloid carcinoma of the intestinal type in the uterine cervix: mucin immunohistochemistry. Pathol Int; 2010 Feb;60(2):119-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colloid carcinoma of the intestinal type in the uterine cervix: mucin immunohistochemistry.
  • A case of colloid carcinoma (gelatinous carcinoma) of the intestinal type in the uterine cervix is reported along with the findings of an immunohistochemical study of intracytoplasmic mucus of the neoplastic cells.
  • The patient was a 69-year-old woman with a circumferential uterine cervical tumor measuring about 4 cm.
  • Colloid carcinoma is a very rare variant of mucus-producing adenocarcinoma of the uterine cervix and probably a heterogeneous group that consists of neoplasms of different histogeneses, that is, neoplasms of endocervical, gastric, and intestinal origins.
  • Results of the immunohistochemical studies in the present case showed that neoplastic cells produced mucus of the large intestine type, thus verifying the presence of a distinct subtype of colloid carcinoma of the cervix that shows the intestinal phenotype.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Mucin-2 / biosynthesis. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398197.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / MUC2 protein, human; 0 / MUC5AC protein, human; 0 / MUC6 protein, human; 0 / Mucin 5AC; 0 / Mucin-2; 0 / Mucin-6
  •  go-up   go-down


54. Peregrin-Alvarez I, Akl MN, Morrow CP, Magrina JF: Metastatic and recurrent adenocarcinoma of the uterine cervix: a long-term survival of 16 years. Eur J Gynaecol Oncol; 2010;31(3):333-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic and recurrent adenocarcinoma of the uterine cervix: a long-term survival of 16 years.
  • PURPOSE OF INVESTIGATION: Recurrent metastatic adenocarcinoma of the cervix is associated with an extremely poor prognosis.
  • CASE REPORT: We report a case of a 43-year-old patient with Stage IB adenocarcinoma of the cervix.
  • CONCLUSION: We conclude that long-term multi-modal salvage treatment may achieve longer survival in rare cases with recurrent metastatic adenocarcinoma of the cervix.
  • [MeSH-major] Adenocarcinoma / therapy. Neoplasm Recurrence, Local / therapy. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21077482.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


55. O'Connell F, Cibas ES: Cytologic features of ciliated adenocarcinoma of the cervix: a case report. Acta Cytol; 2005 Mar-Apr;49(2):187-90
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of ciliated adenocarcinoma of the cervix: a case report.
  • BACKGROUND: Ciliation is a normal finding in the endometrium, fallopian tubes and cervix.
  • Because cilia are characteristically lost when malignant tumors arise at these sites, the detection of cilia on light microscopy is frequently used to support a benign diagnosis.
  • CASE: A woman with a histologically confirmed ciliated adenocarcinoma of the cervix had prior liquid-based cervical cytology showing atypical, ciliated glandular cells that initially raised the diagnostic consideration of tubal metaplasia.
  • A concurrent biopsy, however, revealed focally ciliated adenocarcinoma of the cervix.
  • CONCLUSION: Awareness of the ciliated variant of adenocarcinoma of the cervix is important to avoid overreliance on ciliation as a definitive feature of benignity in cervical cytologic specimens.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Epithelial Cells / pathology. Mullerian Ducts / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Cilia / pathology. Diagnosis, Differential. Diethylstilbestrol / adverse effects. Female. Humans. Pregnancy. Prenatal Exposure Delayed Effects. Vaginal Smears


56. Koo YJ, Lee JE, Hong SR, Kwon YS: Co-occurrence of an adenoma malignum and an endocervical-type adenocarcinoma of the uterine cervix in a woman with Peutz-Jeghers syndrome. J Gynecol Oncol; 2010 Sep;21(3):203-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-occurrence of an adenoma malignum and an endocervical-type adenocarcinoma of the uterine cervix in a woman with Peutz-Jeghers syndrome.
  • We report a rare co-occurrence of an adenoma malignum and an adenocarcinoma in a 30-year-old woman with Peutz-Jeghers syndrome.
  • A pelvic examination and an MRI revealed the co-occurrence of a 4×5 cm protruding adenocarcinoma of FIGO stage Ib2 based on a punch biopsy and a 4.5×5.7 cm multilocular cystic mass above the solid cancer.
  • Pathologic findings were consistent with adenocarcinoma (40%) and adenoma malignum (60%) confined to the cervix.
  • This study will contribute to defining the best diagnosis and treatment for these rare complicating tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20922146.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2948231
  • [Keywords] NOTNLM ; Adenocarcinoma / Adenoma malignum / Peutz-Jeghers syndrome
  •  go-up   go-down


57. Togami S, Nomoto M, Higashi M, Goto M, Yonezawa S, Tsuji T, Batra SK, Douchi T: Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix. J Obstet Gynaecol Res; 2010 Jun;36(3):588-97
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of mucin antigens (MUC1 and MUC16) as a prognostic factor for mucinous adenocarcinoma of the uterine cervix.
  • AIM: Only limited data are available regarding mucin antigen expression in adenocarcinoma of the uterine cervix.
  • METHODS: Fifty-two patients with mucinous adenocarcinoma of the endocervical type were enrolled for making clear implication of the mucin antigens.
  • RESULTS: The majority of mucinous adenocarcinoma showed overexpression of MUC1 and MUC16.
  • In cases classified as FIGO stage Ib (n = 35), after adjusting for patient age at diagnosis and stratifying by histological grade, MUC1 and/or MUC 16 overexpression was an independent prognostic factor for overall survival (hazard ratio [HR] = 6.16, 95% confidence interval [CI] = 1.01-118.5, P < 0.05).
  • CONCLUSION: The expressions of MUC1 and/or MUC16 may be available as independent prognostic factors for the endocervical type of mucinous adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. CA-125 Antigen / metabolism. Membrane Proteins / metabolism. Mucin-1 / metabolism. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology


58. An HJ, Kim KR, Kim IS, Kim DW, Park MH, Park IA, Suh KS, Seo EJ, Sung SH, Sohn JH, Yoon HK, Chang ED, Cho HI, Han JY, Hong SR, Ahn GH: Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mod Pathol; 2005 Apr;18(4):528-34
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study.
  • The role of human papilloma virus (HPV) infection in the development of cervical carcinoma is well established, however, the prevalence of HPV DNA in cervical adenocarcinoma varies from study to study.
  • It appears to be caused by a number of factors, one of which is that cervical adenocarcinomas comprise a heterogeneous group of multiple subtypes.
  • To clarify the impact of HPV infection on the development of cervical adenocarcinoma with diverse histological subtypes, we performed a population-based study in Korean women from 15 different institutes for the status of HPV infection in adenocarcinoma of uterine cervix.
  • A total of 432 cervical adenocarcinomas from 1997 to 2001 were reviewed and classified according to the modified WHO classification.
  • The overall prevalence of HPV infection in cervical adenocarcinoma was 90%.
  • The infection of HPV 16 and/or HPV 18 accounted for 78% of HPV-positive adenocarcinomas.
  • The HPV DNA was rarely detected in minimal deviation adenocarcinoma.
  • In conclusion, HPV infection, mostly HPV 16 and HPV 18, is highly associated with most of the cervical adenocarcinomas, whereas endometrioid and villoglandular type have a different pattern of HPV infection status.
  • Minimal deviation adenocarcinoma does not seem to be related with HPV infection.
  • [MeSH-major] Adenocarcinoma / pathology. DNA, Viral / genetics. Papillomaviridae / genetics. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15502807.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


59. Chargui R, Damak T, Khomsi F, Ben Hassouna J, Chaieb W, Hechiche M, Gamoudi A, Boussen H, Benna F, Rahal K: Prognostic factors and clinicopathologic characteristics of invasive adenocarcinoma of the uterine cervix. Am J Obstet Gynecol; 2006 Jan;194(1):43-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and clinicopathologic characteristics of invasive adenocarcinoma of the uterine cervix.
  • OBJECTIVE: The purpose of this study was to evaluate the outcome of patients with cervical adenocarcinoma and to determine the characteristics and the prognostic factors of this entity.
  • STUDY DESIGN: This retrospective study was done in the Department of Surgical Oncology of the Salah Azaiz Institute of Tunis with 79 cases of invasive adenocarcinoma of the uterine cervix that were collected from 1990 to 1999.
  • Early stages (I, IIa, IIb with 1/3 proximal parametrial invasion) and "pure" type adenocarcinoma were found in 78% and 87% of the cases, respectively.
  • CONCLUSION: This report shows survival and prognostic factors that are similar to those found in previous studies, but unlike the Western countries, our results demonstrate a high rate of early stages and no increase in frequency of cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / pathology. Uterine Cervical Neoplasms / complications. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16389008.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Falcón O, García R, Lubrano A, Morín JC, Andujar M: Successful term delivery following conservative management for villoglandular papillary adenocarcinoma of the uterine cervix: A case report. Gynecol Oncol; 2006 Apr;101(1):168-71
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful term delivery following conservative management for villoglandular papillary adenocarcinoma of the uterine cervix: A case report.
  • BACKGROUND: Villoglandular papillary adenocarcinoma (VPA) is a rare subtype of adenocarcinoma of the uterine cervix.
  • [MeSH-major] Carcinoma, Papillary / surgery. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325894.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Hereter L, Tresserra F, Graupera B, Pascual MA, Martinez MA, Ubeda A: Three-dimensional power Doppler color ultrasonographic features of a minimal deviation adenocarcinoma of the uterine cervix. Eur J Gynaecol Oncol; 2010;31(3):336-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Three-dimensional power Doppler color ultrasonographic features of a minimal deviation adenocarcinoma of the uterine cervix.
  • A case of minimal deviation adenocarcinoma of the cervix in a 34-year-old female is presented.
  • The ultrasonographic and three-dimensional power Doppler color studies revealed a nodular cervical lesion with vascularization more prominent in the center of the nodule but also present at the periphery.
  • The imaging diagnosis was suggestive of a myoma but with more vascularization than a conventional one.
  • [MeSH-major] Adenocarcinoma / ultrasonography. Imaging, Three-Dimensional / methods. Ultrasonography, Doppler, Color / methods. Uterine Cervical Neoplasms / ultrasonography


62. Balci S, Saglam A, Usubutun A: Primary signet-ring cell carcinoma of the cervix: case report and review of the literature. Int J Gynecol Pathol; 2010 Mar;29(2):181-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary signet-ring cell carcinoma of the cervix: case report and review of the literature.
  • Mucinous adenocarcinoma of the cervix has 5 subtypes: endocervical, intestinal, signet-ring cell, minimal deviation, and villoglandular.
  • There are only rare reports of primary signet-ring cell carcinoma of the cervix in the literature.
  • Herein we report a 53-year-old woman with cervical adenocarcinoma with signet-ring cell morphology.
  • DNA extraction from paraffin-embedded tissue revealed the presence of human papilloma virus (HPV) type 18, which supports the cervical origin of the tumor.
  • Signet-ring cell morphology can be observed in both benign and malignant lesions of the uterine cervix.
  • Histological features and immunohistochemical profiles are discussed, and a review of signet-ring cell morphology in the uterine cervix is included.
  • [MeSH-major] Carcinoma, Signet Ring Cell / pathology. Papillomaviridae / genetics. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173504.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


63. Shibata K, Kajiyama H, Yamamoto E, Terauchi M, Ino K, Nomura S, Nawa A, Kawai M, Kikkawa F: Effectiveness of preoperative concurrent chemoradiation therapy (CCRT) for locally advanced adenocarcinoma of cervix. Eur J Surg Oncol; 2009 Jul;35(7):768-72
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of preoperative concurrent chemoradiation therapy (CCRT) for locally advanced adenocarcinoma of cervix.
  • AIM: To determine the efficacy of preoperative concurrent chemoradiation therapy (CCRT) to improve the prognosis of locally advanced adenocarcinoma of the uterine cervix.
  • METHODS: Twenty-five patients with clinical stage IB2-IVB adenocarcinoma of the cervix were received preoperative CCRT.
  • CONCLUSIONS: Preoperative CCRT improves the survival of patients with locally advanced adenocarcinoma of the cervix, with manageable toxicities.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Agents / administration & dosage. Cisplatin / administration & dosage. Radiotherapy, Adjuvant. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18722747.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


64. Dabić MM, Nola M, Tomicić I, Dotlić S, Petrovecki M, Jukić S: Adenocarcinoma of the uterine cervix: prognostic significance of clinicopathologic parameters, flow cytometry analysis and HPV infection. Acta Obstet Gynecol Scand; 2008;87(3):366-72
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the uterine cervix: prognostic significance of clinicopathologic parameters, flow cytometry analysis and HPV infection.
  • BACKGROUND: This study was designed to determine the possible impact of status of human papillomavirus (HPV) infection (no infection, single, multiple infections) on the survival of patients with cervical adenocarcinoma, to correlate the HPV status with other clinicopathologic parameters, and to examine clinical, histological and flow cytometric parameters as predictors of survival in cervical adenocarcinoma.
  • METHODS: The clinical data of 51 patients with adenocarcinoma of the cervix who were treated at the Department of Gynecology and Obstetrics, Zagreb University School of Medicine, from 1978 to 2004 were analysed: age at presentation, menstrual status, clinical stage, relapse, survival.
  • CONCLUSION: Clinical stage and architectural grade are significant predictors for survival of patients with cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / virology. Papillomaviridae / growth & development. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18307079.001).
  • [ISSN] 1600-0412
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


65. Lee HB, Lee YS, Lee KH, Kim CJ, Park JS: A case of advanced gynecologic pelvic tumors showing the diagnostic utility of HPV analysis. J Gynecol Oncol; 2009 Dec;20(4):251-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This may lead to difficulties in determining the origin of the cancer and to distinguish a synchronous neoplasm from a metastatic cancer in advanced cases.
  • Recently, we treated a 59-year-old patient with adenocarcinoma of the uterine cervix, endometrium, fallopian tubes, and ovaries.
  • It was difficult to determine whether the cancer was a single origin metastatic cancer or a synchronous neoplasm.
  • The patient was finally diagnosed with metastatic cancer that originated from the uterine cervix by human papillomavirus (HPV) test.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):281-94 [15725796.001]
  • [Cites] Gynecol Oncol. 1999 Mar;72(3):337-41 [10053104.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):829-36 [15010819.001]
  • [Cites] Tumour Biol. 2003 Nov-Dec;24(6):310-6 [15004491.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):246-50 [11166153.001]
  • [Cites] Br J Cancer. 2003 Aug 18;89(4):672-5 [12915876.001]
  • [Cites] Gynecol Oncol. 2002 Oct;87(1):104-11 [12468350.001]
  • [Cites] Obstet Gynecol. 2002 Nov;100(5 Pt 2):1129-33 [12423833.001]
  • [Cites] Cancer Causes Control. 2001 May;12(4):335-41 [11456229.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jan;23(1):7-12 [14668543.001]
  • (PMID = 20041104.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2799026
  • [Keywords] NOTNLM ; Cervical adenocarcinoma / Human papillomavirus / Metastatic cancer / Synchronous neoplasm
  •  go-up   go-down


66. Xu Y, Ge R, Du J, Xin H, Yi T, Sheng J, Wang Y, Ling C: Corosolic acid induces apoptosis through mitochondrial pathway and caspase activation in human cervix adenocarcinoma HeLa cells. Cancer Lett; 2009 Nov 1;284(2):229-37
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corosolic acid induces apoptosis through mitochondrial pathway and caspase activation in human cervix adenocarcinoma HeLa cells.
  • We investigated the response of human cervix adenocarcinoma HeLa cells to Corosolic acid (CRA) treatment.
  • Taken together, we believe that CRA could have strong potentials for clinical application in treating human cervix adenocarcinoma and improving cancer chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents, Phytogenic / pharmacology. Caspases / physiology. Mitochondria / drug effects. Neoplasm Proteins / physiology. Triterpenes / pharmacology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Ireland Ltd.
  • (PMID = 19457606.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / BAX protein, human; 0 / Drugs, Chinese Herbal; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Triterpenes; 0 / bcl-2-Associated X Protein; 4547-24-4 / corosolic acid; EC 3.4.22.- / Caspases
  •  go-up   go-down


67. Florea AM, Splettstoesser F, Dopp E, Rettenmeier AW, Büsselberg D: Modulation of intracellular calcium homeostasis by trimethyltin chloride in human tumour cells: neuroblastoma SY5Y and cervix adenocarcinoma HeLa S3. Toxicology; 2005 Dec;216(1):1-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of intracellular calcium homeostasis by trimethyltin chloride in human tumour cells: neuroblastoma SY5Y and cervix adenocarcinoma HeLa S3.
  • TMT) modulates calcium homeostasis in cervix adenocarcinoma (HeLa S3) cells [Florea, A.
  • [MeSH-minor] Adenocarcinoma / metabolism. Cell Line, Tumor. Dose-Response Relationship, Drug. Fluorescent Dyes. Humans. Microscopy, Confocal. Neuroblastoma / metabolism

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125831.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Trimethyltin Compounds; 1631-73-8 / trimethyltin; SY7Q814VUP / Calcium
  •  go-up   go-down


68. Odashiro AN, Odashiro DN, Nguyen GK: Minimal deviation endometrioid adenocarcinoma of the cervix: report of three cases with exfoliative cytology. Diagn Cytopathol; 2006 Feb;34(2):119-23
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal deviation endometrioid adenocarcinoma of the cervix: report of three cases with exfoliative cytology.
  • Three histologically confirmed minimal deviation endometrioid adenocarcinomas (MDEA) of the uterine cervix with cytologic evaluation by cervical scraping were reviewed.
  • The cytologic manifestations of those three cervical MDEAs overlapped, to some extents, with those of a cervical adenocarcinoma in situ and with those of a well-differentiated endometrial adenocarcinoma invading the cervix.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16511847.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Millaire M, Alobaid A, Gariépy G, Gauthier P: Metastatic adenocarcinoma of the cervix: a case report. J Obstet Gynaecol Can; 2005 Dec;27(12):1113-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the cervix: a case report.
  • BACKGROUND: Adenocarcinoma metastatic to the cervix is unusual.
  • Very few cases of cervical metastases from gastrointestinal tract primary lesions have been reported in the literature, and most of them lack pathological evidence.
  • CASE: We report the case of a 75-year-old woman with a metastasis to the cervix from a large bowel adenocarcinoma that had been managed by right hemicolectomy 14 months previously.
  • The cervical metastasis was the first sign of recurrence.
  • CONCLUSION: In women with cervical adenocarcinoma and a history of gastrointestinal or breast cancer or melanoma, specific screening should be undertaken to ensure that the cervical disease is not metastatic.
  • The detection of adenocarcinoma in this subset of patients might be an indication of recurrent disease.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Uterine Cervical Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16524530.001).
  • [ISSN] 1701-2163
  • [Journal-full-title] Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC
  • [ISO-abbreviation] J Obstet Gynaecol Can
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


70. Giordano G, D'Adda T, Gnetti L, Merisio C, Gabrielli M, Melpignano M: Villoglandular adenocarcinoma of the cervix: two new cases with morphological and molecular study. Int J Gynecol Pathol; 2007 Apr;26(2):199-204
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular adenocarcinoma of the cervix: two new cases with morphological and molecular study.
  • In this paper, we report 2 new cases of villoglandular papillary adenocarcinoma (VGPA) of the cervix, a rare, well-differentiated form of cervical adenocarcinoma.
  • Morphological criteria for a correct pathological diagnosis were emphasized.
  • Behavioral cofactors, such as HSV infection (types 1 and 2), oral contraceptive use and smoking, involved in the pathogenesis of other cervical malignancies, can be excluded for the present cases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Antibodies, Neoplasm / metabolism. CA-125 Antigen / metabolism. Carcinoembryonic Antigen / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. DNA, Viral / genetics. Diagnosis, Differential. Female. Human papillomavirus 16 / genetics. Humans. Keratin-7 / metabolism. Middle Aged. Papillomavirus Infections / complications. Papillomavirus Infections / genetics


71. Yap OW, Hendrickson MR, Teng NN, Kapp DS: Mesonephric adenocarcinoma of the cervix: a case report and review of the literature. Gynecol Oncol; 2006 Dec;103(3):1155-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesonephric adenocarcinoma of the cervix: a case report and review of the literature.
  • BACKGROUND: Malignant mesonephric tumor arising in the uterine cervix is an exceedingly uncommon variant of cervical adenocarcinoma with only 30 well-documented cases in the literature.
  • CASE: We present a case of a 54-year-old woman with postmenopausal vaginal bleeding who was found to have a stage IB mesonephric adenocarcinoma of the cervix.
  • CONCLUSION: At present there is no consensus on a standardized treatment protocol for malignant mesonephric tumors of the cervix.
  • [MeSH-major] Mesonephroma / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged


72. Liu B, Zhang H, Luo X, Xie Y, Hao J, Zhou Q, Duan X, Wang Y, Zhao W: High-efficiency transfer and expression of AdCMV-p53 in human cervix adenocarcinoma cells induced by subclinical-dose carbon beam radiation. J Cancer Res Clin Oncol; 2009 Jul;135(7):925-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-efficiency transfer and expression of AdCMV-p53 in human cervix adenocarcinoma cells induced by subclinical-dose carbon beam radiation.
  • PURPOSE: The aim of this study is to evaluate the effect of carbon-beam irradiation on adenovirus-mediated p53 transfer in human cervix adenocarcinoma.
  • The percentage of p53 positive cells in the C-beam with AdCMV-p53 groups was 34-55.6% more than that in gamma-ray with AdCMV-p53 groups (p < 0.05), suggesting that subclinical-dose C-beam irradiation could significantly promote exogenous p53 transfer and p53 expression, and extend the duration of p53 expression in the HeLa cells.
  • The survival fractions for the 0.5-1.0 Gy C-beam with AdCMV-p53 groups were 38-43% less than those for the isodose gamma-ray with AdCMV-p53 groups, and 31-40% less than those for the C-beam only groups (p < 0.05).
  • CONCLUSIONS: The subclinical-dose C-beam irradiation could significantly promote the transfer and expression of exogenous p53, extend the duration of p53 expression, and enhance the suppression of p53 on cervix adenocarcinoma cells.
  • [MeSH-major] Adenocarcinoma / therapy. Carbon Radioisotopes / therapeutic use. Gene Transfer Techniques. Genes, p53. Uterine Cervical Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1989 Jun 16;244(4910):1275-81 [2660259.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 1993;46:1-36 [8234781.001]
  • [Cites] Oncogene. 1997 Apr 10;14(14):1735-46 [9135075.001]
  • [Cites] Oncogene. 1995 Nov 2;11(9):1899-905 [7478620.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):631-40 [14751537.001]
  • [Cites] Oncogene. 1996 Jun 6;12 (11):2369-76 [8649777.001]
  • [Cites] Acta Med Okayama. 1997 Feb;51(1):19-23 [9057931.001]
  • [Cites] Cancer Gene Ther. 1999 Mar-Apr;6(2):155-62 [10195882.001]
  • [Cites] J Biochem. 2003 Aug;134(2):219-24 [12966070.001]
  • [Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1984 Nov;46(5):555-68 [6394531.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Science. 1990 Apr 6;248(4951):76-9 [2157286.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4466-71 [12431970.001]
  • [Cites] Ann N Y Acad Sci. 1994 May;720(1):153-159 [28621859.001]
  • [Cites] Cancer Gene Ther. 2000 Sep;7(9):1215-9 [11023193.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4891-3 [8895740.001]
  • [Cites] Nature. 1992 Jun 11;357(6378):455-60 [1608446.001]
  • [Cites] Hum Gene Ther. 1997 Jun 10;8(9):1025-32 [9189760.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5493-7 [15994918.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):609-22 [10653876.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):598-605 [14628125.001]
  • [Cites] Cancer Gene Ther. 1997 Mar-Apr;4(2):129-38 [9080122.001]
  • [Cites] Obstet Gynecol Clin North Am. 1996 Dec;23(4):735-58 [8989774.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1665-71 [9816114.001]
  • [Cites] Cancer J Sci Am. 1999 Nov-Dec;5(6):362-9 [10606478.001]
  • [Cites] J Virol. 1996 Sep;70(9):6497-501 [8709289.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):803-8 [11395250.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):1050-5 [8640760.001]
  • [Cites] Nature. 1993 Oct 21;365(6448):691-2 [7692307.001]
  • [Cites] Am Rev Respir Dis. 1963 Sep;88:SUPPL 394-403 [14064954.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3397-406 [7936668.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2445-9 [10499617.001]
  • [Cites] J Virol. 1994 Dec;68(12):8282-7 [7966621.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):607-16 [10078646.001]
  • [Cites] Cell. 1990 Dec 21;63(6):1129-36 [2175676.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):563-9 [15289857.001]
  • (PMID = 19085001.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 147336-22-9 / Green Fluorescent Proteins
  •  go-up   go-down


73. Odida M, Lloveras B, Guimera N, Weiderpass E: The usefulness of immunohistochemistry in tissue microarrays of Human Papillomavirus negative adenocarcinoma of the uterine cervix. BMC Res Notes; 2010;3:54

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The usefulness of immunohistochemistry in tissue microarrays of Human Papillomavirus negative adenocarcinoma of the uterine cervix.
  • BACKGROUND: The origin of adenocarcinomas presenting on the cervix uteri may be doubtful, i.e. whether it is of cervical or endometrial origin, due to the overlapping morphological features.
  • We aimed to explore the use of immunohistochemistry profiles in tissue microarrays in archived samples of adenocarcinoma (ADC) of the cervix from Uganda that tested negative for HPV DNA.
  • By using immunohistochemistry in 13 HPV negative ADC, endocervical tumour origin was suspected in five CEA positive cases while two out of three vimentin positive samples were probably of endometrial origin, suggesting that CEA and vimentin may be valuable in distinguishing HPV negative cervical adenocarcinomas from endometrial adenocarcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2009 Jun;33(6):914-24 [19295407.001]
  • [Cites] Virchows Arch. 2001 Jul;439(1):55-61 [11499840.001]
  • [Cites] Pathology. 2007 Feb;39(1):97-111 [17365826.001]
  • [Cites] J Cutan Pathol. 2006 Sep;33(9):629-33 [16965338.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:286-92 [16515605.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1091-100 [16648864.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):347-53 [16445657.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1731-9 [9846964.001]
  • [Cites] Pathology. 2003 Oct;35(5):397-401 [14555383.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):3-13 [12807939.001]
  • [Cites] Virchows Arch. 2003 Mar;442(3):271-7 [12647218.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jul;21(3):217-23 [12068166.001]
  • [Cites] Int J Gynecol Pathol. 2002 Jan;21(1):11-5 [11781517.001]
  • [Cites] Am J Surg Pathol. 2007 May;31(5):653-63 [17460447.001]
  • (PMID = 20199664.001).
  • [ISSN] 1756-0500
  • [Journal-full-title] BMC research notes
  • [ISO-abbreviation] BMC Res Notes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2852389
  •  go-up   go-down


74. Amanie J, Pearcey RG, Honore L, Sloboda R: Metastatic adenocarcinoma of the cervix in a delivery-induced traumatic lower vaginal tear. Gynecol Oncol; 2005 Mar;96(3):857-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of the cervix in a delivery-induced traumatic lower vaginal tear.
  • BACKGROUND: Noncontiguous vaginal metastasis is rare in cervical cancer and is usually reported in the context of traumatic implantation.
  • Traumatic vaginal implantation of cervical carcinoma has been documented in episiotomy, port site, or incision scars.
  • [MeSH-major] Adenocarcinoma / secondary. Uterine Cervical Neoplasms / pathology. Vagina / injuries. Vaginal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721438.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Brebi M P, Ili G CG, López M J, García M P, Melo A A, Montenegro H S, Leal R P, Guzmán G P, Roa S JC: [Detection and genotyping of human papillomavirus in biopsies of uterine cervical adenocarcinoma]. Rev Med Chil; 2009 Mar;137(3):377-82
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection and genotyping of human papillomavirus in biopsies of uterine cervical adenocarcinoma].
  • [Transliterated title] Detección y tipificación de virus papiloma humano en adenocarcinoma de cuello uterino mediante reverse line blot, Región de La Araucanía, Chile.
  • BACKGROUND: The genotyping of Human Papillomavirus (HPV) will improve knowledge about the local epidemiological association of this virus with adenocarcinoma.
  • AIM: To determine the frequency of HPV genotypes in biopsies of women with uterine cervical adenocarcinoma in a geographic region of Chile.
  • MATERIALS AND METHODS: Forty-one cervical biopsies with a pathological diagnosis of adenocarcinoma, corresponding to all women diagnosed with this cancer between 2002 and 2004, were analyzed.
  • CONCLUSIONS: In this sample of biopsies, there was a high prevelence of HPV 16 and a low prevalence of HPV 18, which historically has been related to adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Alphapapillomavirus / genetics. Cervix Uteri / virology. Papillomavirus Infections. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - HPV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19621179.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


76. Detournay B, Granados-Canal D, El-Hasnaouil A: [Assessing the incidence of papillomavirus infections in France]. Gynecol Obstet Fertil; 2009 Feb;37(2):125-30
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Estimation de l'incidence des infections à papillomavirus en France.
  • High-risk oncogenic human papillomavirus (HR-HPV) are strongly associated with squamous cell carcinoma and adenocarcinoma of the uterine cervix.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / epidemiology. Papillomavirus Infections / epidemiology. Papillomavirus Vaccines / administration & dosage. Uterine Neoplasms / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19196534.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines
  •  go-up   go-down


77. Ahrens WA, Barrón-Rodriguez LP, McKee M, Rivkees S, Reyes-Múgica M: Clear cell adenocarcinoma of the cervix in a child without in utero exposure to diethylstilbestrol: a case report and review of the literature. Pediatr Dev Pathol; 2005 Nov-Dec;8(6):690-5
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the cervix in a child without in utero exposure to diethylstilbestrol: a case report and review of the literature.
  • We describe the case of a primary cervical tumor in a 6-year-old child that was originally suspected to be an embryonal rhabdomyosarcoma botryoides.
  • Histologic analysis revealed a clear cell adenocarcinoma.
  • Clear cell adenocarcinoma is an extremely rare neoplasm that should be kept in the differential diagnosis of cervicovaginal lesions in children, even in the absence of a clinical history of in utero diethylstilbestrol exposure.
  • [MeSH-major] Adenocarcinoma / pathology. Diethylstilbestrol / adverse effects. Estrogens, Non-Steroidal / adverse effects. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Pregnancy. Prenatal Exposure Delayed Effects. Rhabdomyosarcoma, Embryonal / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16222478.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Non-Steroidal; 731DCA35BT / Diethylstilbestrol
  •  go-up   go-down


78. Song SH, Lee JK, Saw HS, Choi SY, Koo BH, Kim A, Yeom BW, Kim I: Peutz-Jeghers Syndrome with multiple genital tract tumors and breast cancer: a case report with a review of literatures. J Korean Med Sci; 2006 Aug;21(4):752-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peutz-Jeghers Syndrome with multiple genital tract tumors and breast cancer: a case report with a review of literatures.
  • Her previous medical history was PJS and breast cancer.
  • An ovarian sex cord tumor with annular tubules was incidentally diagnosed together with a minimal deviation adenocarcinoma of the uterine cervix and mucinous metaplasia of both the Fallopian tubal mucosa and the endometrium.
  • The clinical significance of the multiple genital tract tumors and breast cancer associated with PJS is reviewed.
  • [MeSH-major] Breast Neoplasms / pathology. Ovarian Neoplasms / pathology. Peutz-Jeghers Syndrome / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adult. Carcinoma, Ductal, Breast / complications. Carcinoma, Ductal, Breast / pathology. Endometrium / pathology. Fallopian Tubes / pathology. Female. Humans. Korea. Metaplasia. Sex Cord-Gonadal Stromal Tumors / complications. Sex Cord-Gonadal Stromal Tumors / pathology


79. Kato K, Suzuka K, Osaki T, Itami M, Tanaka N: Primary hepatoid adenocarcinoma of the uterine cervix. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):1150-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatoid adenocarcinoma of the uterine cervix.
  • Hepatoid adenocarcinoma is characterized histologically by neoplastic epithelial cells that resemble hepatocellular carcinoma (HCC) and produce alpha-fetoprotein (AFP).
  • We describe a case of hepatoid adenocarcinoma of the uterus that, unlike any other previously reported case, was strictly confined to the cervix.
  • A cervical biopsy demonstrated poorly differentiated adenocarcinoma, and hysterectomy and bilateral salpingo-oophorectomy were subsequently performed.
  • Histologically, the lesion consisted of solid sheets of hepatoid cells accompanied with areas of endometroid adenocarcinoma.
  • The tumor cells showed strong and diffuse cytoplasmic immunoreactivity with AFP in both medullary and adenocarcinoma components.
  • To our knowledge, this is the first report of primary hepatoid adenocarcinoma of the uterine cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367323.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 15
  •  go-up   go-down


80. Nagai N, Hirata E, Kusuda T, Mukai K, Arihiro K, Ohama K: Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1187-90
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report.
  • Villoglandular papillary adenocarcinoma (VGPA) of the uterine cervix is a rare neoplasm, and its treatment has rarely been reported.
  • Thus, the combination of docetaxel and cisplatin is suggested to be useful for neoadjuvant chemotherapy of cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / pathology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343210.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


81. Sert B: Robotic port-site and pelvic recurrences after robot-assisted laparoscopic radical hysterectomy for a stage IB1 adenocarcinoma of the cervix with negative lymph nodes. Int J Med Robot; 2010 Jun;6(2):132-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic port-site and pelvic recurrences after robot-assisted laparoscopic radical hysterectomy for a stage IB1 adenocarcinoma of the cervix with negative lymph nodes.
  • BACKGROUND: Port-site metastasis (PSM) following minimally invasive surgery for gynaecological cancer has been recognized as a potential problem over the last two decades.
  • METHODS: A 60 year-old woman with stage Ib1 adenocarcinoma of the cervix was treated with radical hysterectomy, bilateral salpingo-oophorectomy and bilateral pelvic lymph node dissection, using robot-assisted laparoscopy.
  • CONCLUSION: This is the first case report emphasizing the risk of PSM and early pelvic recurrences in robot-assisted laparoscopic radical hysterectomy and bilateral pelvic lymph node dissection for an early-stage cervical adenocarcinoma patient with negative lymph nodes, histologically examined by immunohistochemical ultrastaging.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Hysterectomy / methods. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adnexa Uteri / pathology. Adnexa Uteri / surgery. Amputation. Endometrial Neoplasms / pathology. Endometrial Neoplasms / secondary. Endometrial Neoplasms / surgery. Female. Follow-Up Studies. Gynecologic Surgical Procedures. Humans. Laparoscopy / methods. Lymph Node Excision / methods. Lymph Nodes / pathology. Lymph Nodes / surgery. Middle Aged. Neoplasm Staging. Pelvis / pathology. Pelvis / surgery. Recurrence. Time Factors. Treatment Outcome


82. Nagar YS, Shah N, Rawat S, Kataria T: Intracranial metastases from adenocarcinoma of cervix: a case report. Int J Gynecol Cancer; 2005 May-Jun;15(3):561-3
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracranial metastases from adenocarcinoma of cervix: a case report.
  • Carcinoma of cervix usually spreads contiguously to the adjacent organs, by lymphatics to the pelvic and para-aortic lymph nodes and by hematogenous route to distant organs.
  • We report here a rare case of a 72-year-old woman with carcinoma of cervix, FIGO stage IIA, who developed metastases to the brain.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15882187.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S, Sasajima Y, Tsuda H: Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix. Br J Cancer; 2009 May 5;100(9):1400-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical hysterectomy for FIGO stage I-IIB adenocarcinoma of the uterine cervix.
  • A retrospective analysis was carried out to identify risk factors for survival and relapse in patients with FIGO stage I-IIB cervical adenocarcinoma (AC), who underwent radical hysterectomy, and to compare outcome and spread pattern with those of squamous cell carcinoma (SCC).
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Hysterectomy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery


84. Schmidt D, Horn LC, Kommoss F: [Neuroendocrine carcinomas of the cervix]. Pathologe; 2005 Jul;26(4):262-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine carcinomas of the cervix].
  • [Transliterated title] Neuroendokrine Karzinome der Cervix uteri.
  • Neuroendocrine carcinomas of the cervix are rare.
  • They either occur in pure form or in combination with adenocarcinoma or squamous cell carcinoma.
  • [MeSH-major] Neuroendocrine Tumors / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Age Distribution. Aged. Carcinoma, Squamous Cell / pathology. Female. Humans. Prognosis


85. Korach J, Machtinger R, Perri T, Vicus D, Segal J, Fridman E, Ben-Baruch G: Villoglandular papillary adenocarcinoma of the uterine cervix: a diagnostic challenge. Acta Obstet Gynecol Scand; 2009;88(3):355-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix: a diagnostic challenge.
  • Villoglandular papillary adenocarcinoma (VGA) is a rare subtype of cervical adenocarcinoma.
  • The aim of our study was to evaluate the reliability of histological assessment for pre-treatment diagnosis of VGA.
  • Median age at diagnosis was 38.8 years (range 27-65).
  • The final histological report on the remaining three patients was invasive cervical adenocarcinoma.
  • We conclude that pre-treatment diagnosis should not be based solely on a simple punch biopsy because of its low rate of diagnostic accuracy.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology


86. Ferchichi L, Rammeh-Rommani S, Ben Hammouda S, Sfar R, Farah F, Ben Jilani S, Zermani R: [Endometrioid adenocarcinoma of the uterine cervix associated with mucinous ovarian cystadenocarcinoma]. Gynecol Obstet Fertil; 2006 May;34(5):410-2
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endometrioid adenocarcinoma of the uterine cervix associated with mucinous ovarian cystadenocarcinoma].
  • [Transliterated title] Association d'un adénocarcinome du col de type endométrioïde à un cystadénocarcinome mucineux de l'ovaire.
  • The pathologic findings of the hysterectomy specimen with bilateral salpingoophorectomy showed an ovarian mucinous cystadenocarcinoma associated with an endometrioid adenocarcinoma of the uterine cervix.
  • In the literature, this tumor had been found in association with endocervical adenocarcinoma or with minimal deviation adenocarcinoma (adenoma malignum) of the uterine cervix.
  • However, its association with an endometrioid adenocarcinoma, to our knowledge, has not been reported.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Hysterectomy


87. Gien LT, Beauchemin MC, Thomas G: Adenocarcinoma: a unique cervical cancer. Gynecol Oncol; 2010 Jan;116(1):140-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma: a unique cervical cancer.
  • Adenocarcinoma of the cervix constitutes only approximately 20% of all cervical carcinomas; therefore, specific Level 1 evidence to guide patient management is lacking.
  • As a consequence, our understanding of the natural history and optimal management of adenocarcinoma of the cervix is limited.
  • The optimal management of adenocarcinoma of the cervix continues to be a subject of debate among practitioners as to whether or not it should be different from squamous cell carcinoma and what would constitute this management.
  • The purpose of this review was to give an overview of the current knowledge on adenocarcinoma of the cervix and its differences from squamous cell carcinoma with regard to risk factors, prognosis, survival rates, patterns of recurrence, and response to treatment.
  • This article will focus on possible specific therapeutic directions to explore in the management of locally advanced adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19880165.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


88. International Collaboration of Epidemiological Studies of Cervical Cancer, Appleby P, Beral V, Berrington de González A, Colin D, Franceschi S, Goodill A, Green J, Peto J, Plummer M, Sweetland S: Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer; 2006 Mar 15;118(6):1481-95
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies.
  • Tobacco smoking has been classified as a cause of cervical cancer, but the effect of different patterns of smoking on risk is unclear.
  • The International Collaboration of Epidemiological Studies of Cervical Cancer has brought together and combined individual data on 13,541 women with and 23,017 women without cervical carcinoma, from 23 epidemiological studies.
  • Relative risks (RRs) and 95% confidence intervals (CIs) of carcinoma of the cervix in relation to tobacco smoking were calculated with stratification by study, age, sexual partners, age at first intercourse, oral contraceptive use and parity.
  • Current smokers had a significantly increased risk of squamous cell carcinoma of the cervix compared to never smokers (RR = 1.60 (95% CI: 1.48-1.73), p<0.001).
  • There was no association between smoking and adenocarcinoma of the cervix (RR = 0.89 (0.74-1.06) and 0.89 (0.72-1.10) for current and past smokers respectively), and the differences between the RRs for smoking and squamous cell and adenocarcinoma were statistically significant (current smoking p<0.001 and past smoking p = 0.01).
  • Eight of the studies had tested women for cervical HPV-DNA, and in analyses restricted to women who tested positive, there was a significantly increased risk in current compared to never smokers for squamous cell carcinoma (RR = 1.95 (1.43-2.65)), but not for adenocarcinoma (RR = 1.06 (0.14-7.96)).
  • In summary, smokers are at an increased risk of squamous cell but not of adenocarcinoma of the cervix.
  • [MeSH-major] Smoking / epidemiology. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206285.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral
  •  go-up   go-down


89. Sozen I, Small L, Kowalski M, Mayo SW, Hurwitz CA: Adenocarcinoma of the cervix metastatic from a colon primary and diagnosed from a routine pap smear in a 17-year-old woman: a case report. J Reprod Med; 2005 Oct;50(10):793-5
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the cervix metastatic from a colon primary and diagnosed from a routine pap smear in a 17-year-old woman: a case report.
  • BACKGROUND: Carcinoma metastatic to the uterine cervix is very rare.
  • The Pap smear and cervical biopsy of a 1.5-cm lesion were positive for adenocarcinoma.
  • CONCLUSION: To our knowledge, this was the youngest patient in the literature with colon cancer metastatic to the cervix.
  • This case focuses attention on the diagnostic challenge posed by an incidental finding of a cervical adenocarcinoma in the presence of an asymptomatic primary tumor.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Papanicolaou Test. Sigmoid Neoplasms / diagnosis. Sigmoid Neoplasms / pathology. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / secondary. Vaginal Smears


90. Stefănescu BI: [Adenocarcinoma of the uterine cervix--risk factors]. Rev Med Chir Soc Med Nat Iasi; 2007 Jan-Mar;111(1):155-60
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma of the uterine cervix--risk factors].
  • [Transliterated title] Adenocarcinomul colului uterin--factori de risc.
  • Adenocarcinoma is the second most common malignancy of the uterine cervix following squamous cell carcinoma.
  • The incidence of adenocarcinomas has been increasing, both in absolute numbers and in proportion to squamous carcinomas.
  • It currently constitutes 10-20% of invasive cervical cancers.
  • It is not very clear whether risk factors identified in squamous cell carcinoma of the cervix are shared by cervical adenocarcinoma as well.
  • While infection with the human papillomavirus appears to be the most important cause of both histologic types of cervical cancer, there has been found differences between adenocarcinoma and squamous cell carcinoma regarding the importance of other risk factors such as reproductive history and smoking.
  • [MeSH-major] Adenocarcinoma / etiology. Uterine Cervical Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17595861.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Contraceptive Agents
  • [Number-of-references] 33
  •  go-up   go-down


91. Quint KD, de Koning MN, Geraets DT, Quint WG, Pirog EC: Comprehensive analysis of Human Papillomavirus and Chlamydia trachomatis in in-situ and invasive cervical adenocarcinoma. Gynecol Oncol; 2009 Sep;114(3):390-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive analysis of Human Papillomavirus and Chlamydia trachomatis in in-situ and invasive cervical adenocarcinoma.
  • OBJECTIVE: Chlamydia trachomatis (Ct) has been implicated as a co-factor in cervical carcinogenesis.
  • The goal of the current study was to investigate if Ct may play a role in pathogenesis of cervical adenocarcinoma and, specifically, if there is a co-infection between Ct and Human Papillomavirus (HPV) in cervical adenocarcinomas.
  • The second goal of the study was to determine the distribution of HPV genotypes in most recent cases of in-situ and invasive cervical adenocarcinomas.
  • METHODS: Biopsies of 71 cervical adenocarcinomas (31 in-situ and 40 invasive) were tested for the presence of Ct using two novel PCR assays.
  • All lesions, however, were positive for HPV with the exception of a case of minimal deviation adenocarcinoma.
  • CONCLUSION: The study demonstrated lack of co-infection between Human Papillomavirus and C. trachomatis in in-situ and invasive adenocarcinoma of the uterine cervix.
  • The role of Ct as a carcinogenetic co-factor may be restricted to cervical squamous cell carcinomas.
  • Accounting for type cross-protection, currently available HPV vaccines are likely to prevent close to 100% of HPV-positive cervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / microbiology. Chlamydia Infections / pathology. Chlamydia trachomatis / isolation & purification. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / microbiology
  • [MeSH-minor] Cervical Intraepithelial Neoplasia / microbiology. Cervical Intraepithelial Neoplasia / pathology. Cervical Intraepithelial Neoplasia / virology. DNA, Viral / genetics. Female. Genotype. Humans. Polymerase Chain Reaction


92. Stewart J 3rd, Bevans-Wilkins K, Ye C, Kurtycz DF: Clear-cell endocervical adenocarcinoma in a 19-year-old woman. Diagn Cytopathol; 2006 Dec;34(12):839-42
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear-cell endocervical adenocarcinoma in a 19-year-old woman.
  • The incidence of adenocarcinoma of the cervix is increasing within the US, but this diagnostic category is not typically associated with teenaged patients.
  • A report on a case of a 19-year-old woman, with no history of diethylbestrol exposure in uteri, diagnosed with clear-cell endocervical adenocarcinoma is made.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Uterine Cervical Neoplasms / pathology


93. Ceballos KM, Shaw D, Daya D: Microinvasive cervical adenocarcinoma (FIGO stage 1A tumors): results of surgical staging and outcome analysis. Am J Surg Pathol; 2006 Mar;30(3):370-4
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microinvasive cervical adenocarcinoma (FIGO stage 1A tumors): results of surgical staging and outcome analysis.
  • Although studies suggest that microinvasive cervical adenocarcinoma has an excellent prognosis, none has reported treatment-related complications and many have lacked detailed measurement criteria.
  • Our study looks at the rate of lymph node metastases and outcome, including complications, in patients with FIGO 1A1 and 1A2 adenocarcinomas of the cervix.
  • One patient died of metastatic ovarian carcinoma 82 months after her diagnosis of cervical carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Neoplasm Staging. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16538058.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. McCluggage WG, Shah R, Connolly LE, McBride HA: Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. Int J Gynecol Pathol; 2008 Jan;27(1):92-100
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
  • Most cases of cervical adenocarcinoma in situ (AIS) and adenocarcinoma are of the usual or endocervical type.
  • However, intestinal types of AIS and adenocarcinoma exist.
  • With an intestinal-type adenocarcinoma in the cervix, the question may arise as to whether one is dealing with a primary cervical neoplasm or direct or secondary spread from an intestinal adenocarcinoma.
  • In organs such as the ovary, urinary bladder, esophagus, and gallbladder, intestinal-type glandular epithelium often expresses enteric markers, but this has hardly been studied in the cervix.
  • The purpose of this study was to investigate whether intestinal-type AIS and adenocarcinoma in the cervix express enteric markers and to ascertain whether these antibodies are of value in the distinction from a metastatic intestinal adenocarcinoma.
  • We compared the immunophenotype of these lesions with that of usual-type AIS and adenocarcinomain the cervix.
  • Cases included were AIS of usual type (n = 6), primary cervical adenocarcinoma of usual type (n = 6), AIS of intestinal type (n = 21), primary cervical adenocarcinoma of intestinal type (n = 3), primary cervical adenocarcinoma with signet ring cells (n = 2), and colorectal adenocarcinoma involving the cervix (n = 5).
  • All usual cervical adenocarcinomas were diffusely CK7 and p16 positive, and all were immunoreactive with CEA.
  • The 3 cases of primary cervical intestinal-type adenocarcinoma were diffusely CK7 positive, focally or diffusely positive with CK20 and CDX2, and focally positive with CEA.
  • The foci of signet ring cells in the 2 primary cervical adenocarcinomas were diffusely CK7 and p16 positive and negative with CK20 and CDX2.
  • Colorectal adenocarcinomas involving the cervix were typically diffusely positive with CK20, CEA, and CDX2; negative with CK7; and negative or focally positive with p16.
  • Intestinal types of cervical AIS and adenocarcinoma exhibit a partial enteric immunophenotype, usually with diffuse expression of CDX2 and, in some cases, staining with CK20.
  • Although there is immunophenotypic overlap, focal staining with CK20 together with diffuse CK7 and sometimes p16 positivity helps to distinguish intestinal types of cervical adenocarcinoma from involvement by a colorectal adenocarcinoma; CEA and CDX2 are of no value in this regard.
  • Using a set of cases of AIS diagnosed in a single institution over a 7-year period (77 usual type; 13 intestinal type), intestinal type was more likely to be associated with early invasive adenocarcinoma than usual type (31% vs 17%), suggesting that intestinal differentiation may be a risk factor for invasion in premalignant cervical glandular lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / biosynthesis. Intestinal Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / biosynthesis. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Immunophenotyping. Keratin-20 / biosynthesis. Keratin-7 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156982.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Carcinoembryonic Antigen; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


95. Simionescu C, Georgescu CV, Mărgăritescu C, Niculescu M: Diagnosis problems in a case of minimal deviation adenocarcinoma of the cervix. Rom J Morphol Embryol; 2006;47(3):245-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis problems in a case of minimal deviation adenocarcinoma of the cervix.
  • We present the diagnostic problems in a case of minimal deviation adenocarcinoma of the cervix.
  • The aspect suggested the diagnosis of minimal deviation adenocarcinoma endocervical type; in order to confirm the diagnosis we immunohistochemical investigate the tumor for CEA, CA125, Ki67, ER and PR.
  • We can conclude that all these markers are useful in the diagnosis, excluding the benign endocervical lesions.
  • [MeSH-major] Adenocarcinoma / diagnosis. Uterine Cervical Neoplasms / diagnosis


96. Li G, Jiang W, Gui S, Xu C: Minimal deviation adenocarcinoma of the uterine cervix. Int J Gynaecol Obstet; 2010 Aug;110(2):89-92
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal deviation adenocarcinoma of the uterine cervix.
  • BACKGROUND: Precise preoperative diagnosis of minimal deviation adenocarcinoma (MDA) of the uterine cervix is often difficult because the histological features of MDA closely resemble those of normal cervical glands.
  • OBJECTIVE: To review the developments in the diagnosis and treatment of MDA over the past 35 years.
  • SEARCH STRATEGY: We performed a meta-analysis of all case reports published in the English and Chinese languages between 1975 and 2009 that included a histopathologic diagnosis of MDA.
  • RESULTS: The histopathologic diagnosis of MDA remains difficult and is currently based on antigen detection by immunohistochemistry.
  • Cross-sectional imaging techniques are helpful but a deep cervical biopsy or cervical conization is necessary for a definitive diagnosis.
  • CONCLUSION: Early diagnosis and treatment are key to improving prognosis and survival in patients with MDA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Conization. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Biopsy. Cervix Uteri / cytology. Female. Humans. Immunohistochemistry


97. Mabuchi S, Matsumoto Y, Morii E, Morishige K, Kimura T: The first 2 cases of granulocyte colony-stimulating factor producing adenocarcinoma of the uterine cervix. Int J Gynecol Pathol; 2010 Sep;29(5):483-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The first 2 cases of granulocyte colony-stimulating factor producing adenocarcinoma of the uterine cervix.
  • We report the first 2 cases of G-CSF-producing cervical adenocarcinomas, which exhibited an aggressive clinical course.
  • At initial diagnosis, both patients exhibited marked leukocytosis without an obvious sign of infections.
  • These cases strongly indicate the aggressive nature of the G-CSF-producing cervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Granulocyte Colony-Stimulating Factor / biosynthesis. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736776.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


98. Tjalma WA, Van Waes TR, Van den Eeden LE, Bogers JJ: Role of human papillomavirus in the carcinogenesis of squamous cell carcinoma and adenocarcinoma of the cervix. Best Pract Res Clin Obstet Gynaecol; 2005 Aug;19(4):469-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of human papillomavirus in the carcinogenesis of squamous cell carcinoma and adenocarcinoma of the cervix.
  • In rare cases, this infection may lead to cervical cancer.
  • Virtually all squamous cell carcinomas and the overwhelming majority of adenocarcinomas of the cervix are HPV positive.
  • Integration is essential for the onset of cervical carcinogenesis, but is probably not sufficient for progression to invasive cervical cancers.
  • It is likely that several cofactors, such as environmental, viral and host-related factors, are necessary for the development of cervical cancer.
  • This article will address the role of HPV in cervical carcinogenesis as well as the molecular biology involved in the process.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Squamous Cell / virology. Papillomavirus Infections / complications. Sexually Transmitted Diseases, Viral / complications. Uterine Cervical Neoplasms / virology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150388.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53
  • [Number-of-references] 100
  •  go-up   go-down


99. Hao H, Tsujimoto M, Tsubamoto H, Komori S, Hirota S: Immunohistochemical phenotype of the urinary bladder endocervicosis: comparison with normal endocervix and well-differentiated mucinous adenocarcinoma of uterine cervix. Pathol Int; 2010 Jul;60(7):528-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical phenotype of the urinary bladder endocervicosis: comparison with normal endocervix and well-differentiated mucinous adenocarcinoma of uterine cervix.
  • Immunohistochemical phenotype of these glands was compared with three normal uterine endocervices and two cases of well-differentiated mucinous adenocarcinoma of the uterine cervix.
  • On the other hand, only glands of well-differentiated mucinous adenocarcinoma expressed human gastric mucin and showed high proliferative index of Ki-67.
  • Furthermore, diffuse distribution of estrogen and progesterone receptors, lack of human gastric mucin and low proliferative activity were distinct features for endocervicosis compared to well-differentiated mucinous adenocarcinoma.
  • [MeSH-major] Cervix Uteri. Choristoma / pathology. Urinary Bladder Diseases / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / pathology. Adult. Cesarean Section. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Phenotype. Pregnancy. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology


100. McCluggage WG, Hurrell DP, Kennedy K: Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol; 2010 May;34(5):735-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
  • Metastatic tumors within the cervix are uncommon if one excludes endometrial carcinoma, which involves the cervix by direct spread.
  • A variety of other neoplasms rarely metastasize to the cervix and, in most cases, the diagnosis is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.
  • We describe 6 cases of metastatic adenocarcinoma involving the cervix with superficial "mucosal" involvement mimicking primary cervical adenocarcinoma or adenocarcinoma in situ.
  • In 5 cases, the primary adenocarcinoma was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.
  • In the other case, the primary neoplasm was in the pancreas and this was initially interpreted as a primary cervical adenocarcinoma.
  • In the cases of primary ovarian or peritoneal carcinoma, the mucosal tumor within the cervix, which was discovered at the same time as the ovarian or peritoneal neoplasm, raised the possibility of synchronous independent lesions or metastasis from the cervix to the ovary or peritoneum.
  • Positive staining for WT1, p53, and estrogen receptor in the cases of serous carcinoma and an absence of human papillomavirus by linear array genotyping in all cases was of value in excluding a primary cervical neoplasm, although these ancillary studies are supplementary to microscopic examination.
  • In those cases with an ovarian or peritoneal primary, the likely pathogenesis of the cervical involvement is transtubal and intrauterine spread.
  • It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous diagnosis of a primary cervical adenocarcinoma or adenocarcinoma in situ.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged






Advertisement